<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DOCETAXEL- docetaxel solution </strong><br>Sagent Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use docetaxel injection concentrate safely and effectively. See full prescribing information for docetaxel injection concentrate. <br>Docetaxel Injection Concentrate<br>Intravenous Infusion (IV)<br>
Initial U.S. Approval: 1996
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: TOXIC <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span>, HEPATOTOXICITY, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li>
<span class="Bold">Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel injection concentrate at 100 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">(<a href="#s38">5.1</a>)</span>
</li>
<li><span class="Bold">Should not be given if bilirubin &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle (<a href="#s89">8.6</a>)</span></li>
<li>
<span class="Bold">Should not be given if neutrophil counts are &lt;1500 cells/mm</span><span class="Bold"><span class="Sup">3</span></span><span class="Bold">. Obtain frequent blood counts to monitor for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<a href="#s36">4</a>)</span>
</li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, including very rare fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of docetaxel injection concentrate and administration of appropriate therapy (<a href="#s43">5.4</a>)</span></li>
<li><span class="Bold">Contraindicated if history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to docetaxel injection concentrate or to drugs formulated with polysorbate 80 (<a href="#s36">4</a>)</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> may occur despite dexamethasone (<a href="#s44">5.5</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: TOXIC <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span>, HEPATOTOXICITY, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li>
<span class="Bold">Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel injection concentrate at 100 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">(<a href="#s38">5.1</a>)</span>
</li>
<li><span class="Bold">Should not be given if bilirubin &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle (<a href="#s89">8.6</a>)</span></li>
<li>
<span class="Bold">Should not be given if neutrophil counts are &lt;1500 cells/mm</span><span class="Bold"><span class="Sup">3</span></span><span class="Bold">. Obtain frequent blood counts to monitor for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<a href="#s36">4</a>)</span>
</li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, including very rare fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of docetaxel injection concentrate and administration of appropriate therapy (<a href="#s43">5.4</a>)</span></li>
<li><span class="Bold">Contraindicated if history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to docetaxel injection concentrate or to drugs formulated with polysorbate 80 (<a href="#s36">4</a>)</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> may occur despite dexamethasone (<a href="#s44">5.5</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Docetaxel injection concentrate is a microtubule inhibitor indicated for:
 </p>
<ul class="Disc">
<li>
<span class="Bold">Breast Cancer (BC):</span> single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (<a href="#s4">1.1</a>)
</li>
<li>
<span class="Bold">Non-Small Cell Lung Cancer (NSCLC):</span> single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (<a href="#s5">1.2</a>)
</li>
<li>
<span class="Bold">Hormone Refractory Prostate Cancer (HRPC):</span> with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (<a href="#s6">1.3</a>)
</li>
<li>
<span class="Bold">Gastric Adenocarcinoma (GC):</span> with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (<a href="#s7">1.4</a>)
</li>
<li>
<span class="Bold">Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):</span> with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (<a href="#s8">1.5</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Administer in a facility equipped to manage possible complications (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>). Administer intravenously (IV) over 1 hr every 3 weeks. PVC equipment is not recommended. <span class="Bold">Use only a 21 gauge needle to withdraw docetaxel injection concentrate from the vial.</span> </p>
<ul class="Disc">
<li>
<span class="Bold">BC locally advanced or metastatic:</span> 60 mg/m<span class="Sup">2</span> to 100 mg/m<span class="Sup">2</span> single agent (<a href="#s10">2.1</a>)
</li>
<li>
<span class="Bold">BC adjuvant:</span> 75 mg/m<span class="Sup">2</span> administered 1 hour after doxorubicin 50 mg/m<span class="Sup">2</span> and cyclophosphamide 500 mg/m<span class="Sup">2</span> every 3 weeks for 6 cycles (<a href="#s10">2.1</a>)
</li>
<li>
<span class="Bold">NSCLC:</span> after platinum therapy failure: 75 mg/m<span class="Sup">2</span> single agent (<a href="#s11">2.2</a>)
</li>
<li>
<span class="Bold">NSCLC:</span> chemotherapy-naive: 75 mg/m<span class="Sup">2</span> followed by cisplatin 75 mg/m<span class="Sup">2</span> (<a href="#s11">2.2</a>)
</li>
<li>
<span class="Bold">HRPC:</span> 75 mg/m<span class="Sup">2</span> with 5 mg prednisone twice a day continuously (<a href="#s12">2.3</a>)
</li>
<li>
<span class="Bold">GC:</span> 75 mg/m<span class="Sup">2</span> followed by cisplatin 75 mg/m<span class="Sup">2</span> (both on day 1 only) followed by fluorouracil 750 mg/m<span class="Sup">2</span> per day as a 24-hr IV (days 1 to 5), starting at end of cisplatin infusion (<a href="#s13">2.4</a>)
</li>
<li>
<span class="Bold">SCCHN:</span> 75 mg/m<span class="Sup">2</span> followed by cisplatin 75 mg/m<span class="Sup">2</span> IV (day 1), followed by fluorouracil 750 mg/m<span class="Sup">2</span> per day as a 24-hr IV (days 1 to 5), starting at end of cisplatin infusion; for 4 cycles (<a href="#s14">2.5</a>)
</li>
<li>
<span class="Bold">SCCHN:</span> 75 mg/m<span class="Sup">2</span> followed by cisplatin 100 mg/m<span class="Sup">2</span> IV (day 1), followed by fluorouracil 1000 mg/m<span class="Sup">2</span> per day as a 24-hr IV (days 1 to 4); for 3 cycles (<a href="#s14">2.5</a>)
</li>
</ul>
<p class="Highlighta"><span class="Bold">For all patients:</span> </p>
<ul class="Disc">
<li>Premedicate with oral corticosteroids (<a href="#s15">2.6</a>)
</li>
<li>Adjust dose as needed (<a href="#s16">2.7</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>One vial docetaxel injection concentrate: Single use vials 20 mg/mL, 80 mg/4 mL and 140 mg /7 mL (<a href="#s34">3</a>)
</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to docetaxel or polysorbate 80 (<a href="#s36">4</a>)
</li>
<li>Neutrophil counts of &lt;1500 cells/mm<span class="Sup">3</span> (<a href="#s36">4</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute myeloid leukemia</span>:</span> In patients who received docetaxel injection concentrate, doxorubicin and cyclophosphamide, monitor for delayed <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span> or <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myeloid leukemia</span> (<a href="#s45">5.6</a>).
</li>
<li>
<span class="Bold">Cutaneous reactions:</span>  Reactions including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the extremities with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> followed by <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> may occur.  Severe skin toxicity may require dose adjustment (<a href="#s46">5.7</a>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic reactions</span>:</span> Reactions including. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may occur.  Severe neurosensory symptoms require dose adjustment or discontinuation if persistent (<a href="#s47">5.8</a>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>:</span> Severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> may occur and may require treatment discontinuation (<a href="#s48">5.9</a>).
</li>
<li>
<span class="Bold">Pregnancy:</span> Fetal harm can occur when administered to a pregnant woman.  Women of childbearing potential should be advised not to become pregnant when receiving docetaxel injection concentrate (<a href="#s49">5.10</a>, <a href="#s80">8.1</a>).
</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions across all docetaxel injection concentrate indications are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (<a href="#s50">6</a>).
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism (<a href="#s78">7</a>).
</li></ul></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: TOXIC <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span>, HEPATOTOXICITY, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span>
</a></h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Breast Cancer
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Non-Small Cell Lung Cancer
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prostate Cancer
</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Gastric Adenocarcinoma
</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Head and Neck Cancer
</a></h2>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Breast Cancer
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Non-Small Cell Lung Cancer
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Prostate Cancer
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Gastric Adenocarcinoma
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Head and Neck Cancer
</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Premedication Regimen
</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Dosage Adjustments During Treatment
</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Administration Precautions
</a></h2>
<h2><a href="#section-2.9" class="toc">2.9 Preparation and Administration
</a></h2>
<h2><a href="#section-2.10" class="toc">2.10 Stability
</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hematologic Effects
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute Myeloid Leukemia</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Cutaneous Reactions
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Reactions</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Use in Pregnancy
</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experiences
</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Human Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Locally Advanced or Metastatic Breast Cancer
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Adjuvant Treatment of Breast Cancer
</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Non-Small Cell Lung Cancer (NSCLC)
</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Hormone Refractory Prostate Cancer
</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Gastric Adenocarcinoma
</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Head and Neck Cancer
</a></h2>
<h1><a href="#section-14" class="toc">15. REFERENCES
</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied
</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage
</a></h2>
<h2><a href="#section-15.3" class="toc">16.3 Handling and Disposal
</a></h2>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: TOXIC <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span>, HEPATOTOXICITY, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span>
</h1>
<p class="First"><span class="Bold">The incidence of treatment-related mortality associated with docetaxel injection concentrate therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel injection concentrate as a single agent at a dose of 100 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s38">5.1</a>)]</span>.
</p>
<p><span class="Bold">Docetaxel injection concentrate should not be given to patients with bilirubin &gt;upper limit of normal (ULN), or to patients with AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, severe <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, severe skin toxicity, and toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients with isolated elevations of transaminase &gt;1.5 x ULN also had a higher rate of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> grade 4 but did not have an increased incidence of toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Bilirubin, AST or ALT, and alkaline phosphatase values should be obtained prior to each cycle of docetaxel injection concentrate therapy
</span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s41">5.2</a>)]</span><span class="Bold">. Docetaxel injection concentrate therapy should not be given to patients with neutrophil counts of &lt;1500 cells/mm</span><span class="Bold"><span class="Sup">3</span></span><span class="Bold">. In order to monitor the occurrence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which may be severe and result in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, frequent blood cell counts should be performed on all patients receiving docetaxel injection concentrate
</span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s42">5.3</a>)]</span>.
</p>
<p><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> characterized by generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, or very rarely fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported in patients who received a 3-day dexamethasone premedication. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> require immediate discontinuation of the docetaxel injection concentrate infusion and administration of appropriate therapy
</span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s43">5.4</a>)]</span><span class="Bold">. Docetaxel injection concentrate must not be given to patients who have a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to docetaxel injection concentrate or to other drugs formulated with polysorbate 80
</span><span class="Bold Italics">[see Contraindications (<a href="#s36">4</a>)]</span>.
</p>
<p><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> occurred in 6.5% (6/92) of patients despite use of a 3-day dexamethasone premedication regimen. It was characterized by one or more of the following events: poorly tolerated <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> requiring urgent drainage, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at rest, <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>, or pronounced abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> (due to <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>)
</span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s44">5.5</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Breast Cancer
</h2>
<p class="First">Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
</p>
<p>Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Non-Small Cell Lung Cancer
</h2>
<p class="First">Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
</p>
<p>Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prostate Cancer
</h2>
<p class="First">Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Gastric Adenocarcinoma
</h2>
<p class="First">Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Head and Neck Cancer
</h2>
<p class="First">Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s9"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION
</h1>
<p class="First">For all indications, toxicities may warrant dosage adjustments <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</p>
<p>Administer in a facility equipped to manage possible complications (e.g. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Breast Cancer
</h2>
<ul class="Disc">
<li>For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of docetaxel injection concentrate is 60 mg/m<span class="Sup">2</span> to 100 mg/m<span class="Sup">2</span> administered intravenously over 1 hour every 3 weeks.
</li>
<li>For the adjuvant treatment of operable node-positive breast cancer, the recommended docetaxel injection concentrate dose is 75 mg/m<span class="Sup">2</span> administered 1 hour after doxorubicin 50 mg/m<span class="Sup">2</span> and cyclophosphamide 500 mg/m<span class="Sup">2</span> every 3 weeks for 6 courses. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> G-CSF may be used to mitigate the risk of hematological toxicities <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Non-Small Cell Lung Cancer
</h2>
<ul class="Disc">
<li>For treatment after failure of prior platinum-based chemotherapy, docetaxel injection concentrate was evaluated as monotherapy, and the recommended dose is 75 mg/m<span class="Sup">2</span> administered intravenously over 1 hour every 3 weeks. A dose of 100 mg/m<span class="Sup">2</span> in patients previously treated with chemotherapy was associated with increased hematologic toxicity, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and treatment-related mortality in randomized, controlled trials <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Dosage and Administration (<a href="#s16">2.7</a>), Warnings and Precautions (<a href="#s37">5</a>), Clinical Studies (<a href="#s108">14</a>)]</span>.
</li>
<li>For chemotherapy-naïve patients, docetaxel injection concentrate was evaluated in combination with cisplatin. The recommended dose of docetaxel injection concentrate is 75 mg/m<span class="Sup">2</span> administered intravenously over 1 hour immediately followed by cisplatin 75 mg/m<span class="Sup">2</span> over 30 to 60 minutes every 3 weeks <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Prostate Cancer
</h2>
<ul class="Disc"><li>For hormone-refractory metastatic prostate cancer, the recommended dose of docetaxel injection concentrate is 75 mg/m<span class="Sup">2</span> every 3 weeks as a 1 hour intravenous infusion. Prednisone 5 mg orally twice daily is administered continuously <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Gastric Adenocarcinoma
</h2>
<ul class="Disc"><li>For gastric adenocarcinoma, the recommended dose of docetaxel injection concentrate is 75 mg/m<span class="Sup">2</span> as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m<span class="Sup">2</span>, as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m<span class="Sup">2</span> per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Head and Neck Cancer
</h2>
<p class="First">Patients must receive premedication with antiemetics, and appropriate hydration (prior to and after cisplatin administration). Prophylaxis for neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> should be administered. All patients treated on the docetaxel injection concentrate containing arms of the TAX323 and TAX324 studies received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotics.
</p>
<ul class="Disc">
<li>
<span class="Italics">Induction chemotherapy followed by radiotherapy (TAX323)<br></span>For the induction treatment of locally advanced inoperable SCCHN, the recommended dose of docetaxel injection concentrate is 75 mg/m<span class="Sup">2</span> as a 1 hour intravenous infusion followed by cisplatin 75 mg/m<span class="Sup">2</span> intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg/m<span class="Sup">2</span> per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy. <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li>
<li>
<span class="Italics">Induction chemotherapy followed by chemoradiotherapy (TAX324) <br></span>For the induction treatment of patients with locally advanced (unresectable, low surgical cure, or organ preservation) SCCHN, the recommended dose of docetaxel injection concentrate is 75 mg/m<span class="Sup">2</span> as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m<span class="Sup">2</span> administered as a 30-minute to 3 hour infusion, followed by fluorouracil 1000 mg/m<span class="Sup">2</span>/day as a continuous infusion from day 1 to day 4. This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive chemoradiotherapy <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Premedication Regimen
</h2>
<p class="First">All patients should be premedicated with oral corticosteroids (see below for prostate cancer) such as dexamethasone 16 mg per day (e.g., 8 mg twice daily) for 3 days starting 1 day prior to docetaxel injection concentrate administration in order to reduce the incidence and severity of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> as well as the severity of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s43">5.4</a>)]</span>.
</p>
<p>For hormone-refractory metastatic prostate cancer, given the concurrent use of prednisone, the recommended premedication regimen is oral dexamethasone 8 mg, at 12 hours, 3 hours and 1 hour before the docetaxel injection concentrate infusion <span class="Italics">[see Warnings and Precautions (<a href="#s43">5.4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Dosage Adjustments During Treatment
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.7.1"></a><p></p>
<p class="First"><span class="Underline">Breast Cancer</span></p>
<p>Patients who are dosed initially at 100 mg/m<span class="Sup">2</span> and who experience either <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;500 cells/mm<span class="Sup">3</span> for more than 1 week, or severe or cumulative cutaneous reactions during docetaxel injection concentrate therapy should have the dosage adjusted from 100 mg/m<span class="Sup">2</span> to 75 mg/m<span class="Sup">2</span>. If the patient continues to experience these reactions, the dosage should either be decreased from 75 mg/m<span class="Sup">2</span> to 55 mg/m<span class="Sup">2</span> or the treatment should be discontinued. Conversely, patients who are dosed initially at 60 mg/m<span class="Sup">2</span> and who do not experience <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;500 cells/mm<span class="Sup">3</span> for more than 1 week, severe or cumulative cutaneous reactions, or severe <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> during docetaxel injection concentrate therapy may tolerate higher doses. Patients who develop ≥grade 3 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> should have docetaxel injection concentrate treatment discontinued entirely.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.7.2"></a><p></p>
<p class="First"><span class="Underline">Combination Therapy with Docetaxel Injection Concentrate in the Adjuvant Treatment of Breast Cancer</span></p>
<p>Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide should be administered when the neutrophil count is ≥1,500 cells/mm<span class="Sup">3</span>. Patients who experience <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their docetaxel injection concentrate dose reduced to 60 mg/m<span class="Sup">2</span>. Patients who experience grade 3 or 4 <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> should have their docetaxel injection concentrate dose decreased to 60 mg/m<span class="Sup">2</span>. Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel injection concentrate therapy should have their dosage of docetaxel injection concentrate reduced from 75 mg/m<span class="Sup">2</span> to 60 mg/m<span class="Sup">2</span>. If the patient continues to experience these reactions at 60 mg/m<span class="Sup">2</span>, treatment should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-2.7.3"></a><p></p>
<p class="First"><span class="Underline">Non-Small Cell Lung Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-2.7.4"></a><p></p>
<p class="First"><span class="Italics">Monotherapy with docetaxel injection concentrate for NSCLC treatment after failure of prior platinum-based chemotherapy</span></p>
<p>Patients who are dosed initially at 75 mg/m<span class="Sup">2</span> and who experience either <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;500 cells/mm<span class="Sup">3</span> for more than one week, severe or cumulative cutaneous reactions, or other grade 3/4 non-hematological toxicities during docetaxel injection concentrate treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg/m<span class="Sup">2</span>. Patients who develop ≥grade 3 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> should have docetaxel injection concentrate treatment discontinued entirely.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.7.5"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with docetaxel injection concentrate for chemotherapy-naïve NSCLC</span></p>
<p>For patients who are dosed initially at docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is &lt;25,000 cells/mm<span class="Sup">3</span>, in patients who experience <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, and in patients with serious non-hematologic toxicities, the docetaxel injection concentrate dosage in subsequent cycles should be reduced to 65 mg/m<span class="Sup">2</span>. In patients who require a further dose reduction, a dose of 50 mg/m<span class="Sup">2</span> is recommended. For cisplatin dosage adjustments, see manufacturers' prescribing information.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-2.7.6"></a><p></p>
<p class="First"><span class="Underline">Prostate Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-2.7.7"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with docetaxel injection concentrate for hormone-refractory metastatic prostate cancer</span></p>
<p>Docetaxel injection concentrate should be administered when the neutrophil count is ≥1,500 cells/mm<span class="Sup">3</span>. Patients who experience either <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;500 cells/mm<span class="Sup">3</span> for more than one week, severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel injection concentrate therapy should have the dosage of docetaxel injection concentrate reduced from 75 mg/m<span class="Sup">2</span> to 60 mg/m<span class="Sup">2</span>. If the patient continues to experience these reactions at 60 mg/m<span class="Sup">2</span>, the treatment should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-2.7.8"></a><p></p>
<p class="First"><span class="Underline">Gastric or Head and Neck Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-2.7.9"></a><p></p>
<p class="First"><span class="Italics">Docetaxel injection concentrate in combination with cisplatin and fluorouracil in gastric cancer or head and neck cancer</span></p>
<p>Patients treated with docetaxel injection concentrate in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. In both studies, G-CSF was recommended during the second and/or subsequent cycles in case of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, or documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> lasting more than 7 days. If an episode of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, prolonged <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs despite G-CSF use, the docetaxel injection concentrate dose should be reduced from 75 mg/m<span class="Sup">2</span> to 60 mg/m<span class="Sup">2</span>. If subsequent episodes of complicated <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occur the docetaxel injection concentrate dose should be reduced from 60 mg/m<span class="Sup">2</span> to 45 mg/m<span class="Sup">2</span>. In case of grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> the docetaxel injection concentrate dose should be reduced from 75 mg/m<span class="Sup">2</span> to 60 mg/m<span class="Sup">2</span>. Patients should not be retreated with subsequent cycles of docetaxel injection concentrate until <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> recover to a level &gt;1,500 cells/mm<span class="Sup">3</span> and platelets recover to a level &gt;100,000 cells/mm<span class="Sup">3</span>. Discontinue treatment if these toxicities persist. <span class="Italics">[see Warnings and Precautions (<a href="#s42">5.3</a>)]</span>.
</p>
<p>Recommended dose modifications for toxicities in patients treated with docetaxel injection concentrate in combination with cisplatin and fluorouracil are shown in <a href="#t1">Table 1</a>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1 - Recommended Dose Modifications for Toxicities in Patients Treated with Docetaxel Injection Concentrate in Combination with Cisplatin and Fluorouracil
</span></caption>
<col align="left" width="34.200%">
<col align="left" width="65.800%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Toxicity</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Dosage adjustment</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> grade 3
</td>
<td class="Botrule Rrule" align="left" valign="top">First episode: reduce fluorouracil dose by 20%. Second episode: then reduce docetaxel injection concentrate dose by 20%.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> grade 4
</td>
<td class="Botrule Rrule" align="left" valign="top">First episode: reduce docetaxel injection concentrate and fluorouracil doses by 20%. Second episode: discontinue treatment.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> grade 3
</td>
<td class="Botrule Rrule" align="left" valign="top">First episode: reduce fluorouracil dose by 20%. Second episode: stop fluorouracil only, at all subsequent cycles. Third episode: reduce docetaxel injection concentrate dose by 20%.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> grade 4
</td>
<td class="Botrule Rrule" align="left" valign="top">First episode: stop fluorouracil only, at all subsequent cycles. Second episode: reduce docetaxel injection concentrate dose by 20%.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-2.7.10"></a><p></p>
<p class="First"><span class="Bold">Liver dysfunction:</span></p>
<p>In case of AST/ALT &gt;2.5 to ≤5 x ULN and AP ≤2.5 x ULN, or AST/ALT &gt;1.5 to ≤5 x ULN and AP &gt;2.5 to ≤5 x ULN, docetaxel injection concentrate should be reduced by 20%.
</p>
<p>In case of AST/ALT &gt;5 x ULN and/or AP &gt;5 x ULN docetaxel injection concentrate should be stopped.
</p>
<p>The dose modifications for cisplatin and fluorouracil in the gastric cancer study are provided
</p>
<p>below:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-2.7.11"></a><p></p>
<p class="First"><span class="Underline">Cisplatin dose modifications and delays</span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: A neurological examination should be performed before entry into the study, and then at least every 2 cycles and at the end of treatment. In the case of neurological signs or symptoms, more frequent examinations should be performed and the following dose modifications can be made according to NCIC-CTC grade:
</p>
<ul class="Disc">
<li>Grade 2: Reduce cisplatin dose by 20%.
</li>
<li>Grade 3: Discontinue treatment.
</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>: In the case of grade 3 toxicity, discontinue treatment.
</p>
<p><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>: In the event of a rise in serum creatinine ≥grade 2 (&gt;1.5 x normal value) despite adequate rehydration, CrCl should be determined before each subsequent cycle and the following dose reductions should be considered (see <a href="#t2">Table 2</a>).
</p>
<p>For other cisplatin dosage adjustments, also refer to the manufacturers' prescribing information.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 – Dose Reductions for Evaluation of Creatinine Clearance
</span></caption>
<col align="left" width="37.200%">
<col align="left" width="62.800%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">CrCl = Creatinine clearance
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="top"><span class="Bold">Creatinine clearance result before next cycle</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Cisplatin dose next cycle</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">CrCl ≥60 mL/min
</td>
<td class="Botrule Rrule" align="left" valign="top">Full dose of cisplatin was given. CrCl was to be repeated before each treatment cycle.
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">CrCl between 40 and 59 mL/min
</td>
<td class="Botrule Rrule" align="left" valign="top">Dose of cisplatin was reduced by 50% at subsequent cycle. If CrCl was &gt;60 mL/min at end of cycle, full cisplatin dose was reinstituted at the next cycle.<br><br>If no recovery was observed, then cisplatin was omitted from the next treatment cycle.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">CrCl &lt;40 mL/min
</td>
<td class="Botrule Rrule" align="left" valign="top">Dose of cisplatin was omitted in that treatment cycle only.<br><br>If CrCl was still &lt;40 mL/min at the end of cycle, cisplatin was discontinued.<br><br>If CrCl was &gt;40 and &lt;60 mL/min at end of cycle, a 50% cisplatin dose was given at the next cycle.<br><br>If CrCl was &gt;60 mL/min at end of cycle, full cisplatin dose was given at next cycle.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-2.7.12"></a><p></p>
<p class="First"><span class="Underline">Fluorouracil dose modifications and treatment delays</span></p>
<p>For <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, see <a href="#t1">Table 1</a>.
</p>
<p>In the event of grade 2 or greater plantar-palmar toxicity, fluorouracil should be stopped until recovery. The fluorouracil dosage should be reduced by 20%.
</p>
<p>For other greater than grade 3 toxicities, except <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, chemotherapy should be delayed (for a maximum of 2 weeks from the planned date of infusion) until resolution to grade ≤1 and then recommenced, if medically appropriate.
</p>
<p>For other fluorouracil dosage adjustments, also refer to the manufacturers' prescribing information.
</p>
<p>Combination Therapy with Strong CYP3A4 inhibitors:
</p>
<p>Avoid using concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole). There are no clinical data with a dose adjustment in patients receiving strong CYP3A4 inhibitors. Based on extrapolation from a pharmacokinetic study with ketoconazole in 7 patients, consider a 50% docetaxel dose reduction if patients require co-administration of a strong CYP3A4 inhibitor <span class="Italics">[see Drug Interactions (<a href="#s78">7</a>), Clinical Pharmacology (<a href="#s95">12.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Administration Precautions
</h2>
<p class="First">Docetaxel injection concentrate is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing docetaxel injection concentrate solutions. The use of gloves is recommended. Please refer to <span class="Italics">[see How Supplied/ Storage and Handling (<a href="#s126">16.3</a>)]</span>.
</p>
<p>If docetaxel injection concentrate, or diluted infusion solution should come into contact with the skin or mucosa, wash immediately and thoroughly with soap and water.
</p>
<p>Do not use plasticized PVC equipment or devices that comes in direct contact with docetaxel injection solution during preparation and administration of docetaxel injection solutions for infusion. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may leach from PVC infusion bags or sets, the diluted docetaxel infusion solution should be stored in bottles made of glass, polypropylene or plastic bags made with polypropylene, polyolefin and administered through polyethylene-lined administration sets.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-2.8.1"></a><p></p>
<p class="First"><span class="Bold Underline">One-vial Docetaxel Injection Concentrate</span></p>
<p>Docetaxel injection concentrate requires no prior dilution with a diluent and is ready to be added to the infusion solution.
</p>
<p>Please follow the preparation instructions provided below.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-2.9"></a><p></p>
<h2>2.9 Preparation and Administration
</h2>
<p class="First">Do not use the two-vial formulation (Injection Concentrate and diluent) with the one-vial formulation.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-2.9.1"></a><p></p>
<p class="First"><span class="Bold Underline">One-vial Docetaxel Injection Concentrate</span></p>
<p>Docetaxel injection concentrate (20 mg/mL) requires no prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21 gauge needle to withdraw docetaxel injection concentrate from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates.
</p>
<ol class="Arabic">
<li>Docetaxel injection concentrate vials should be stored at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) protected from light.
</li>
<li>Using <span class="Bold">only</span> a 21 gauge needle, aseptically withdraw the required amount of docetaxel injection concentrate (20 mg docetaxel/mL) with a calibrated syringe and inject into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 mg/mL to 0.74 mg/mL. If a dose greater than 200 mg of docetaxel injection concentrate is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL docetaxel injection concentrate is not exceeded.
</li>
<li>Thoroughly mix the infusion solution by gentle manual rotation.
</li>
<li>As with all parenteral products, docetaxel injection concentrate should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the docetaxel injection concentrate dilution for intravenous infusion is not clear or appears to have precipitation, it should be discarded.
</li>
</ol>
<p>The docetaxel injection concentrate dilution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-2.10"></a><p></p>
<h2>2.10 Stability
</h2>
<p class="First">Docetaxel injection concentrate dilution for infusion is stable for 4 hours, if stored between 2°C and 25°C (36°F and 77°F). Docetaxel injection concentrate dilution for infusion (in either 0.9% Sodium Chloride solution or 5% Dextrose solution) should be used within 4 hours (including the 1 hour intravenous administration).
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s34"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold Underline">One-vial Docetaxel Injection Concentrate</span></p>
<p>Docetaxel Injection Concentrate is available as 20 mg/mL, 80 mg/4 mL and 140 mg /7 mL. Each mL contains 20 mg docetaxel, citric acid anhydrous (6 mg), Povidone (kollidon 12 PF) (100 mg), polysorbate 80 (424 mg) and ethanol (400 mg/mL).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s36"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS
</h1>
<ul class="Disc">
<li>Docetaxel injection concentrate is contraindicated in patients who have a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to docetaxel or to other drugs formulated with polysorbate 80. Severe reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have occurred <span class="Italics">[see Warnings and Precautions (<a href="#s43">5.4</a>)]</span>.
</li>
<li>Docetaxel injection concentrate should not be used in patients with neutrophil counts of &lt;1500 cells/mm<span class="Sup">3</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s37"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Underline">Breast Cancer</span></p>
<p>Docetaxel injection concentrate administered at 100 mg/m<span class="Sup">2</span> was associated with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> considered possibly or probably related to treatment in 2.0% (19/965) of metastatic breast cancer patients, both previously treated and untreated, with normal baseline liver function and in 11.5% (7/61) of patients with various tumor types who had abnormal baseline liver function (AST and/or ALT &gt;1.5 times ULN together with AP &gt;2.5 times ULN). Among patients dosed at 60 mg/m<span class="Sup">2</span>, mortality related to treatment occurred in 0.6% (3/481) of patients with normal liver function, and in 3 of 7 patients with abnormal liver function. Approximately half of these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred during the first cycle. <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> accounted for the majority of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.1.2"></a><p></p>
<p class="First"><span class="Underline">Non-Small Cell Lung Cancer</span></p>
<p>Docetaxel injection concentrate administered at a dose of 100 mg/m<span class="Sup">2</span> in patients with locally advanced or metastatic non-small cell lung cancer who had a history of prior platinum-based chemotherapy was associated with increased treatment-related mortality (14% and 5% in two randomized, controlled studies). There were 2.8% treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> among the 176 patients treated at the 75 mg/m<span class="Sup">2</span> dose in the randomized trials. Among patients who experienced treatment-related mortality at the 75 mg/m<span class="Sup">2</span> dose level, 3 of 5 patients had an ECOG PS of 2 at study entry <span class="Italics">[see Dosage and Administration (<a href="#s11">2.2</a>), Clinical Studies (<a href="#s108">14</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with Docetaxel Injection Concentrate <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Use in Specific Populations (<a href="#s89">8.6</a>), Clinical studies (<a href="#s108">14</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hematologic Effects
</h2>
<p class="First">Perform frequent peripheral blood cell counts on all patients receiving docetaxel injection concentrate. Patients should not be retreated with subsequent cycles of docetaxel injection concentrate until <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> recover to a level &gt;1500 cells/mm<span class="Sup">3</span> and platelets recover to a level &gt; 100,000 cells/mm<span class="Sup">3</span>.
</p>
<p>A 25% reduction in the dose of docetaxel injection concentrate is recommended during subsequent cycles following severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (&lt;500 cells/mm<span class="Sup">3</span>) lasting 7 days or more, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, or a grade 4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in a docetaxel injection concentrate cycle <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;2000 <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>/mm<span class="Sup">3</span>) occurs in virtually all patients given 60 mg/m<span class="Sup">2</span> to 100 mg/m<span class="Sup">2</span> of docetaxel injection concentrate and grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (&lt;500 cells/mm<span class="Sup">3</span>) occurs in 85% of patients given 100 mg/m<span class="Sup">2</span> and 75% of patients given 60 mg/m<span class="Sup">2</span>. Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Docetaxel injection concentrate should not be administered to patients with <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;1500 cells/mm<span class="Sup">3</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> occurred in about 12% of patients given 100 mg/m<span class="Sup">2</span> but was very uncommon in patients given 60 mg/m<span class="Sup">2</span>. Hematologic responses, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reactions</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and rates of septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> for different regimens are dose related <span class="Italics">[see Adverse Reactions (<a href="#s51">6.1</a>), Clinical Studies (<a href="#s108">14</a>)]</span>.
</p>
<p>Three breast cancer patients with severe liver impairment (bilirubin &gt;1.7 times ULN) developed fatal <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> associated with severe drug-induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> and/or neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurred in 12% of patients receiving G-CSF compared to 28% who did not. Patients receiving TCF should be closely monitored during the first and subsequent cycles for <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> and neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>), Adverse Reactions (<a href="#s50">6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First">Patients should be observed closely for <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, especially during the first and second infusions. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> characterized by generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, or very rarely fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported in patients premedicated with 3 days of corticosteroids. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> require immediate discontinuation of the docetaxel injection concentrate infusion and aggressive therapy. Patients with a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should not be rechallenged with docetaxel injection concentrate.
</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may occur within a few minutes following initiation of a docetaxel injection concentrate infusion. If minor reactions such as <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">localized skin reactions</span> occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of docetaxel injection concentrate <span class="Italics">[see Dosage and Administration (<a href="#s15">2.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>
</h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> has been reported following docetaxel injection concentrate therapy. Patients should be premedicated with oral corticosteroids prior to each docetaxel injection concentrate administration to reduce the incidence and severity of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> <span class="Italics">[see Dosage and Administration (<a href="#s15">2.6</a>)]</span>. Patients with pre-existing <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusions</span> should be closely monitored from the first dose for the possible exacerbation of the <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusions</span>.
</p>
<p>When <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> occurs, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> usually starts in the lower extremities and may become generalized with a median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 2 kg.
</p>
<p>Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> occurred in 27.2% and severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> in 6.5%. The median cumulative dose to onset of moderate or severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> was 819 mg/m<span class="Sup">2</span>. Nine of 92 patients (9.8%) of patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>: 4 patients discontinued with severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>; the remaining 5 had mild or moderate <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. The median cumulative dose to treatment discontinuation due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> was 1021 mg/m<span class="Sup">2</span>. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of docetaxel injection concentrate to resolution (range: 0 to 42+ weeks). Patients developing <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> may be treated with standard measures, e.g., salt restriction, oral diuretic(s).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute Myeloid Leukemia</span>
</h2>
<p class="First">Treatment-related <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> (AML) or <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span> has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In the adjuvant breast cancer trial <span class="Italics">(TAX316)</span> AML occurred in 3 of 744 patients who received docetaxel injection concentrate, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin and cyclophosphamide <span class="Italics">[see Clinical Studies (<a href="#s112">14.2</a>)]</span>. In TAC-treated patients, the risk of delayed <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span> or <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myeloid leukemia</span> requires hematological follow-up.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Cutaneous Reactions
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Localized erythema</span> of the extremities with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> followed by <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued docetaxel injection concentrate due to skin toxicity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Reactions</span>
</h2>
<p class="First">Severe neurosensory symptoms (e.g. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>)]</span>. Patients who experienced <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe <span class="product-label-link" type="condition" conceptid="4319472" conceptname="Peripheral motor neuropathy">peripheral motor neuropathy</span> mainly manifested as distal extremity <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> occurred in 4.4% (42/965).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Use in Pregnancy
</h2>
<p class="First">Docetaxel injection concentrate can cause fetal harm when administered to a pregnant woman. Docetaxel caused embryofetal toxicities including intrauterine mortality when administered to pregnant rats and rabbits during the period of organogenesis. Embryofetal effects in animals occurred at doses as low as 1/50 and 1/300 the recommended human dose on a body surface area basis.
</p>
<p>There are no adequate and well-controlled studies in pregnant women using docetaxel injection concentrate. If docetaxel injection concentrate is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with docetaxel injection concentrate <span class="Italics">[see Use in Specific Populations (<a href="#s80">8.1</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s50"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS
</h1>
<p class="First">The most serious adverse reactions from docetaxel injection concentrate are:
</p>
<ul class="Disc">
<li>Toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warning and Precautions (<a href="#s38">5.1</a>)]</span>
</li>
<li>Hepatotoxicity <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s41">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s42">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s43">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s44">5.5</a>)]</span>
</li>
</ul>
<p>The most common adverse reactions across all docetaxel injection concentrate indications are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Incidence varies depending on the indication.
</p>
<p>Adverse reactions are described according to indication. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Breast Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Monotherapy with Docetaxel injection concentrate for locally advanced or metastatic breast cancer after failure of prior chemotherapy</span></p>
<p>Docetaxel injection concentrate 100 mg/m<span class="Sup">2</span>: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received docetaxel injection concentrate administered at 100 mg/m<span class="Sup">2</span> as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to docetaxel injection concentrate. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving docetaxel injection concentrate for the treatment of breast cancer and in patients with other tumor types (See <a href="#t3">Table 3</a>).
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3 - Summary of Adverse Reactions in Patients Receiving Docetaxel Injection Concentrate at 100 mg/m<span class="Sup">2</span></span></caption>
<col align="left" width="32.200%">
<col align="left" width="24.675%">
<col align="left" width="22.875%">
<col align="left" width="20.250%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">**Elevated Baseline LFTs: AST and/or ALT &gt;1.5 times ULN concurrent with alkaline phosphatase &gt;2.5 times ULN
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">***<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span>: ANC grade 4 with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;38°C with intravenous antibiotics and/or hospitalization
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">All Tumor Types</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">All Tumor Types</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Breast Cancer</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Elevated LFTs**</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=2045</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=61</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=965</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Hematologic</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   &lt;2000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="bottom">96
</td>
<td class="Rrule" align="center" valign="bottom">96
</td>
<td class="Rrule" align="center" valign="bottom">99
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   &lt;500 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="top">75
</td>
<td class="Rrule" align="center" valign="top">88
</td>
<td class="Rrule" align="center" valign="top">86
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   &lt;4000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="bottom">96
</td>
<td class="Rrule" align="center" valign="bottom">98
</td>
<td class="Rrule" align="center" valign="bottom">99
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   &lt;1000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="top">32
</td>
<td class="Rrule" align="center" valign="top">47
</td>
<td class="Rrule" align="center" valign="top">44
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   &lt;100,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="top">8
</td>
<td class="Rrule" align="center" valign="top">25
</td>
<td class="Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   &lt;11 g/dL
</td>
<td class="Rrule" align="center" valign="middle">90
</td>
<td class="Rrule" align="center" valign="middle">92
</td>
<td class="Rrule" align="center" valign="middle">94
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   &lt;8 g/dL
</td>
<td class="Rrule" align="center" valign="middle">9
</td>
<td class="Rrule" align="center" valign="middle">31
</td>
<td class="Rrule" align="center" valign="middle">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span>***
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
<td class="Botrule Rrule" align="center" valign="middle">26
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Rrule" align="center" valign="top">2
</td>
<td class="Rrule" align="center" valign="top">5
</td>
<td class="Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Non-Septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">22
</td>
<td class="Rrule" align="center" valign="bottom">33
</td>
<td class="Rrule" align="center" valign="bottom">22
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">16
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in Absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="top">31
</td>
<td class="Rrule" align="center" valign="top">41
</td>
<td class="Rrule" align="center" valign="top">35
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Regardless of Premedication
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">21
</td>
<td class="Rrule" align="center" valign="bottom">20
</td>
<td class="Rrule" align="center" valign="bottom">18
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Rrule" align="center" valign="bottom">4
</td>
<td class="Rrule" align="center" valign="bottom">10
</td>
<td class="Rrule" align="center" valign="bottom">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">With 3-day Premedication
</td>
<td class="Rrule" align="center" valign="bottom">n=92
</td>
<td class="Rrule" align="center" valign="bottom">n=3
</td>
<td class="Rrule" align="center" valign="bottom">n=92
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">15
</td>
<td class="Rrule" align="center" valign="bottom">33
</td>
<td class="Rrule" align="center" valign="bottom">15
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Regardless of Premedication
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">47
</td>
<td class="Rrule" align="center" valign="bottom">39
</td>
<td class="Rrule" align="center" valign="bottom">60
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Rrule" align="center" valign="bottom">7
</td>
<td class="Rrule" align="center" valign="bottom">8
</td>
<td class="Rrule" align="center" valign="bottom">9
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">With 3-day Premedication
</td>
<td class="Rrule" align="center" valign="bottom">n=92
</td>
<td class="Rrule" align="center" valign="bottom">n=3
</td>
<td class="Rrule" align="center" valign="bottom">n=92
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">64
</td>
<td class="Rrule" align="center" valign="bottom">67
</td>
<td class="Rrule" align="center" valign="bottom">64
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
<td class="Botrule Rrule" align="center" valign="bottom">33
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neurosensory</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">49
</td>
<td class="Rrule" align="center" valign="bottom">34
</td>
<td class="Rrule" align="center" valign="bottom">58
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Cutaneous</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">48
</td>
<td class="Rrule" align="center" valign="bottom">54
</td>
<td class="Rrule" align="center" valign="bottom">47
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">10
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Changes</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">31
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
<td class="Rrule" align="center" valign="bottom">41
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Rrule" align="center" valign="bottom">39
</td>
<td class="Rrule" align="center" valign="bottom">38
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Rrule" align="center" valign="bottom">22
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Rrule" align="center" valign="bottom">39
</td>
<td class="Rrule" align="center" valign="bottom">33
</td>
<td class="Rrule" align="center" valign="bottom">43
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
<td class="Rrule" align="center" valign="bottom">49
</td>
<td class="Rrule" align="center" valign="bottom">52
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">13
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">76
</td>
<td class="Botrule Rrule" align="center" valign="top">62
</td>
<td class="Botrule Rrule" align="center" valign="top">74
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">62
</td>
<td class="Rrule" align="center" valign="bottom">53
</td>
<td class="Rrule" align="center" valign="bottom">66
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">19
</td>
<td class="Rrule" align="center" valign="bottom">16
</td>
<td class="Rrule" align="center" valign="bottom">21
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Infusion Site Reactions</span></td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Hematologic Reactions</span></p>
<p>Reversible marrow suppression was the major dose-limiting toxicity of docetaxel injection concentrate <span class="Italics">[see Warnings and Precautions (<a href="#s42">5.3</a>)]</span>. The median time to nadir was 7 days, while the median duration of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (&lt;500 cells/mm<span class="Sup">3</span>) was 7 days. Among 2045 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> and normal baseline LFTs, severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 75.4% and lasted for more than 7 days in 2.9% of cycles.
</p>
<p><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> (&lt;500 cells/mm<span class="Sup">3</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;38°C with intravenous antibiotics and/or hospitalization) occurred in 11% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, in 12.3% of patients with metastatic breast cancer, and in 9.8% of 92 breast cancer patients premedicated with 3-day corticosteroids.
</p>
<p>Severe infectious episodes occurred in 6.1% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, in 6.4% of patients with metastatic breast cancer, and in 5.4% of 92 breast cancer patients premedicated with 3-day corticosteroids.
</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (&lt;100,000 cells/mm<span class="Sup">3</span>) associated with fatal <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> has been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s43">5.4</a>)]</span>. Minor events, including <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with or without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, have been reported and resolved after discontinuing the infusion and instituting appropriate therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> can occur with the use of docetaxel injection concentrate <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Dosage and Administration (<a href="#s15">2.6</a>), Warnings and Precautions (<a href="#s44">5.5</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold">Cutaneous Reactions</span></p>
<p>Severe skin toxicity is discussed elsewhere in the label <span class="Italics">[see Warnings and Precautions (<a href="#s46">5.7</a>)]</span>. Reversible cutaneous reactions characterized by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> including localized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>, mainly on the feet and/or hands, but also on the arms, face, or thorax, usually associated with <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, have been observed. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Eruptions</span> generally occurred within 1 week after docetaxel injection concentrate infusion, recovered before the next infusion, and were not disabling.
</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span> were characterized by hypo- or hyperpigmentation, and occasionally by <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">onycholysis</span> (in 0.8% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>) and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic reactions</span> are discussed elsewhere in the label <span class="Italics">[see Warnings and Precautions (<a href="#s47">5.8</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were generally mild to moderate. Severe reactions occurred in 3 to 5% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> and to a similar extent among metastatic breast cancer patients. The incidence of severe reactions was 1% or less for the 92 breast cancer patients premedicated with 3-day corticosteroids.
</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> occurred in 5.5% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, in 7.4% of patients with metastatic breast cancer, and in 1.1% of the 92 breast cancer patients premedicated with 3-day corticosteroids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-6.1.9"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular Reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> occurred in 2.8% of patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>; 1.2% required treatment. Clinically meaningful events such as <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, dysrhythmia, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> occurred rarely. Seven of 86 (8.1%) of metastatic breast cancer patients receiving docetaxel injection concentrate 100 mg/m<span class="Sup">2</span> in a randomized trial and who had serial left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fractions</span> assessed developed deterioration of LVEF by ≥10% associated with a drop below the institutional lower limit of normal.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-6.1.10"></a><p></p>
<p class="First"><span class="Bold">Infusion Site Reactions</span></p>
<p>Infusion site reactions were generally mild and consisted of hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or dryness of the skin, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the vein.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-6.1.11"></a><p></p>
<p class="First"><span class="Bold">Hepatic Reactions</span></p>
<p>In patients with normal LFTs at baseline, bilirubin values greater than the ULN occurred in 8.9% of patients. Increases in AST or ALT &gt;1.5 times the ULN, or alkaline phosphatase &gt;2.5 times ULN, were observed in 18.9% and 7.3% of patients, respectively. While on docetaxel injection concentrate, increases in AST and/or ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN occurred in 4.3% of patients with normal LFTs at baseline. Whether these changes were related to the drug or underlying disease has not been established.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-6.1.12"></a><p></p>
<p class="First"><span class="Bold">Hematologic and Other Toxicity: Relation to dose and baseline liver chemistry abnormalities</span></p>
<p>Hematologic and other toxicity is increased at higher doses and in patients with elevated baseline liver function tests (LFTs). In the following tables, adverse drug reactions are compared for three populations: 730 patients with normal LFTs given docetaxel injection concentrate at 100 mg/m<span class="Sup">2</span> in the randomized and single arm studies of metastatic breast cancer after failure of previous chemotherapy; 18 patients in these studies who had abnormal baseline LFTs (defined as AST and/or ALT &gt;1.5 times ULN concurrent with alkaline phosphatase &gt;2.5 times ULN); and 174 patients in Japanese studies given docetaxel injection concentrate at 60 mg/m<span class="Sup">2</span> who had normal LFTs (see <a href="#t4">Tables 4</a> and <a href="#t5">5</a>).
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4 - Hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Docetaxel Injection Concentrate 100 mg/m<span class="Sup">2</span> with Normal or Elevated Liver Function Tests or 60 mg/m<span class="Sup">2</span> with Normal Liver Function Tests
</span></caption>
<col align="left" width="17.956%">
<col align="left" width="17.956%">
<col align="left" width="18.756%">
<col align="left" width="15.177%">
<col align="left" width="30.154%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">*Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote">**Elevated Baseline LFTs: AST and/or ALT &gt;1.5 times ULN concurrent with alkaline phosphatase &gt;2.5 times ULN
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote">***Incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> requiring hospitalization and/or intravenous antibiotics was 8.5% (n=62) among the 730 patients with normal LFTs at baseline; 7 patients had concurrent grade 3 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and 46 patients had grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">****<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span>: For 100 mg/m<span class="Sup">2</span>, ANC grade 4 and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;38°C with intravenous antibiotics and/or hospitalization; for 60 mg/m<span class="Sup">2</span>, ANC grade 3/4 and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;38.1°C
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" colspan="2" valign="bottom"></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<span class="Bold">100 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">60 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Elevated LFTs**</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=730</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=18</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=174</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="bottom">98
</td>
<td class="Rrule" align="center" valign="bottom">100
</td>
<td class="Rrule" align="center" valign="bottom">95
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">   Grade 4
</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;500 cells/mm<span class="Sup">3</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">84
</td>
<td class="Botrule Rrule" align="center" valign="bottom">94
</td>
<td class="Botrule Rrule" align="center" valign="bottom">75
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="left" valign="top">&lt;100,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center" valign="bottom">11
</td>
<td class="Rrule" align="center" valign="bottom">44
</td>
<td class="Rrule" align="center" valign="bottom">14
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">   Grade 4
</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;20,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;11 g/dL
</td>
<td class="Botrule Rrule" align="center" valign="top">95
</td>
<td class="Botrule Rrule" align="center" valign="top">94
</td>
<td class="Botrule Rrule" align="center" valign="top">65
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>***</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
<td class="Rrule" align="center" valign="bottom">39
</td>
<td class="Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">   Grade 3 and 4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
<td class="Botrule Rrule" align="center" valign="bottom">33
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span>****</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">   By Patient
</td>
<td class="Rrule" align="center" valign="bottom">12
</td>
<td class="Rrule" align="center" valign="bottom">33
</td>
<td class="Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">   By Course
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">9
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Non-Septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<a name="t5"></a><table width="100%">
<caption><span>Table 5 - Non-Hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Docetaxel Injection Concentrate 100 mg/m<span class="Sup">2</span> with Normal or Elevated Liver Function Tests or 60 mg/m<span class="Sup">2</span> with Normal Liver Function Tests
</span></caption>
<col align="left" width="31.100%">
<col align="left" width="15.025%">
<col align="left" width="19.425%">
<col align="left" width="34.450%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">** Elevated Baseline Liver Function: AST and/or ALT &gt;1.5 times ULN concurrent with alkaline phosphatase &gt;2.5 times ULN
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">***<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> includes (by COSTART): <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (peripheral, localized, generalized, <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> otherwise not specified) and <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> (pleural, pericardial, and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>); no premedication given with the 60 mg/m<span class="Sup">2</span> dose
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">NA = not available
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<span class="Bold">100 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">60 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Elevated LFTs**</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Normal LFTs*</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=730</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=18</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=174</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Reaction Regardless of</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Premedication</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Any
</td>
<td class="Rrule" align="center" valign="bottom">13
</td>
<td class="Rrule" align="center" valign="bottom">6
</td>
<td class="Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>***</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Regardless of Premedication</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Any
</td>
<td class="Rrule" align="center" valign="bottom">56
</td>
<td class="Rrule" align="center" valign="bottom">61
</td>
<td class="Rrule" align="center" valign="bottom">13
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neurosensory</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">       Any
</td>
<td class="Rrule" align="center" valign="bottom">57
</td>
<td class="Rrule" align="center" valign="bottom">50
</td>
<td class="Rrule" align="center" valign="bottom">20
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">23
</td>
<td class="Botrule Rrule" align="center" valign="top">33
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Cutaneous</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">       Any
</td>
<td class="Rrule" align="center" valign="bottom">45
</td>
<td class="Rrule" align="center" valign="bottom">61
</td>
<td class="Rrule" align="center" valign="bottom">31
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">       Any
</td>
<td class="Rrule" align="center" valign="bottom">65
</td>
<td class="Rrule" align="center" valign="bottom">44
</td>
<td class="Rrule" align="center" valign="bottom">66
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17
</td>
<td class="Botrule Rrule" align="center" valign="bottom">22
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">       Any
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
<td class="Rrule" align="center" valign="bottom">28
</td>
<td class="Rrule" align="center" valign="middle">NA
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">       Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">11
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">       Any
</td>
<td class="Rrule" align="center" valign="bottom">53
</td>
<td class="Rrule" align="center" valign="bottom">67
</td>
<td class="Rrule" align="center" valign="bottom">19
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">       Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">39
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
</tr>
</tbody>
</table>
<p>In the three-arm monotherapy trial, TAX313, which compared docetaxel injection concentrate 60 mg/m<span class="Sup">2</span>, 75 mg/m<span class="Sup">2</span> and 100 mg/m<span class="Sup">2</span> in advanced breast cancer, grade 3/4 or severe adverse reactions occurred in 49.0% of patients treated with docetaxel injection concentrate 60 mg/m<span class="Sup">2</span> compared to 55.3% and 65.9% treated with 75 mg/m<span class="Sup">2</span> and 100 mg/m<span class="Sup">2</span> respectively. Discontinuation due to adverse reactions was reported in 5.3% of patients treated with 60 mg/m<span class="Sup">2</span> vs. 6.9% and 16.5% for patients treated at 75 and 100 mg/m<span class="Sup">2</span> respectively. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> within 30 days of last treatment occurred in 4.0% of patients treated with 60 mg/m<span class="Sup">2</span> compared to 5.3% and 1.6% for patients treated at 75 mg/m<span class="Sup">2</span> and 100 mg/m<span class="Sup">2</span> respectively.
</p>
<p>The following adverse reactions were associated with increasing docetaxel doses: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> (26%, 38%, and 46% at 60 mg/m<span class="Sup">2</span>, 75 mg/m<span class="Sup">2</span>, and 100 mg/m<span class="Sup">2</span> respectively), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (7%, 11% and 12% respectively), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (92%, 94%, and 97% respectively), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (5%, 7%, and 14% respectively), treatment-related grade 3/4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (2%, 3%, and 7% respectively) and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (87%, 94%, and 97% respectively).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e63"></a><a name="section-6.1.13"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with docetaxel injection concentrate in the adjuvant treatment of breast cancer</span></p>
<p>The following table presents treatment emergent adverse reactions observed in 744 patients, who were treated with docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> every 3 weeks in combination with doxorubicin and cyclophosphamide (see <a href="#t6">Table 6</a>).
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6- Clinically Important Treatment Emergent Adverse Reactions Regardless of Causal Relationship in Patients Receiving Docetaxel Injection Concentrate in Combination with Doxorubicin and Cyclophosphamide (TAX316).
</span></caption>
<col align="left" width="27.325%">
<col align="left" width="21.024%">
<col align="left" width="18.384%">
<col align="left" width="15.863%">
<col align="left" width="17.403%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* COSTART term and grading system for events related to treatment.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">+</span>
</td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Fluorouracil 500 mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">+</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Doxorubicin 50 mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">+</span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Doxorubicin 50 mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">+</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Cyclophosphamide 500 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">(TAC)</span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Cyclophosphamide 500 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">(FAC)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">n=744 <br>%</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">n=736 <br>%</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Grade 3/4</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Grade 3/4</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">92
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">72
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">71
</td>
<td class="Botrule Rrule" align="center" valign="top">66
</td>
<td class="Botrule Rrule" align="center" valign="top">82
</td>
<td class="Botrule Rrule" align="center" valign="top">49
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">47
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">17
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">39
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">36
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">39
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">28
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">Lymphedema</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>*</span></td>
<td class="Rrule" align="center" valign="top">35
</td>
<td class="Rrule" align="center" valign="top">1
</td>
<td class="Rrule" align="center" valign="top">15
</td>
<td class="Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>
</td>
<td class="Rrule" align="center" valign="top">27
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">7
</td>
<td class="Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> sensory</span></td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neuro-cortical</span></td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> motor</span></td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neuro-cerebellar</span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">98
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">97
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Skin toxicity</span></td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">81
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">88
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">69
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">53
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">45
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">59
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">35
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">28
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">34
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">32
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">28
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">22
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">62
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">52
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac dysrhythmias</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">81
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">71
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span> disorder</span></td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<p>Of the 744 patients treated with TAC, 36.3% experienced severe treatment emergent adverse reactions compared to 26.6% of the 736 patients treated with FAC. Dose reductions due to hematologic toxicity occurred in 1% of cycles in the TAC arm versus 0.1% of cycles in the FAC arm. Six percent of patients treated with TAC discontinued treatment due to adverse reactions, compared to 1.1% treated with FAC; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in the absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> being the most common reasons for withdrawal among TAC-treated patients. Two patients died in each arm within 30 days of their last study treatment; 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> per arm was attributed to study drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-6.1.14"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in the absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was seen in 46.5% of TAC-treated patients and in 17.1% of FAC-treated patients. Grade 3/4 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in the absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was seen in 1.3% and 0% of TAC- and FAC-treated patients respectively. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> was seen in 39.4% of TAC-treated patients compared to 36.3% of FAC-treated patients. Grade 3/4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was seen in 3.9% and 2.2% of TAC-treated and FAC-treated patients respectively. There were no septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in either treatment arm.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-6.1.15"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Reactions</span></p>
<p>In addition to gastrointestinal reactions reflected in the table above, 7 patients in the TAC arm were reported to have <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>/<span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>/<span class="product-label-link" type="condition" conceptid="4177183" conceptname="Perforation of colon">large intestine perforation</span> vs. one patient in the FAC arm. Five of the 7 TAC-treated patients required treatment discontinuation; no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to these events occurred.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-6.1.16"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular Reactions</span></p>
<p>More cardiovascular reactions were reported in the TAC arm vs. the FAC arm; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, all grades (7.9% vs. 6.0%), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, all grades (2.6% vs. 1.1%) and CHF (2.3% vs. 0.9%, at 70 months median follow-up). One patient in each arm died due to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-6.1.17"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute Myeloid Leukemia</span> (AML)</span></p>
<p>Treatment-related <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> or <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span> is known to occur in patients treated with anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. AML occurs at a higher frequency when these agents are given in combination with radiation therapy. AML occurred in the adjuvant breast cancer trial (TAX316). The cumulative risk of developing treatment-related AML at 5 years in TAX316 was 0.4% for TAC-treated patients and 0.1% for FAC-treated patients. This risk of AML is comparable to the risk observed for other anthracyclines/cyclophosphamide containing adjuvant breast chemotherapy regimens.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-6.1.18"></a><p></p>
<p class="First"><span class="Underline">Lung Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-6.1.19"></a><p></p>
<p class="First"><span class="Italics">Monotherapy with Docetaxel injection concentrate for unresectable, locally advanced or metastatic NSCLC previously treated with platinum-based chemotherapy</span></p>
<p>Docetaxel injection concentrate 75 mg/m<span class="Sup">2</span>: Treatment emergent adverse drug reactions are shown in <a href="#t7">Table 7</a>. Included in this table are safety data for a total of 176 patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who were treated in two randomized, controlled trials. These reactions were described using NCI Common Toxicity Criteria regardless of relationship to study treatment, except for the hematologic toxicities or where otherwise noted.
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7 - Treatment Emergent Adverse Reactions Regardless of Relationship to Treatment in Patients Receiving Docetaxel Injection Concentrate as Monotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy*
</span></caption>
<col align="left" width="26.693%">
<col align="left" width="31.817%">
<col align="left" width="20.895%">
<col align="left" width="20.595%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">**<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span>: ANC grade 4 with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;38°C with intravenous antibiotics and/or hospitalization
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">***COSTART term and grading system
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">†</span>Not Applicable; <span class="Sup">††</span> Not Done
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
<td class="Rrule Toprule" align="center" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Vinorelbine/</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Best Supportive Care</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Ifosfamide</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=176</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=49</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=119</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">84
</td>
<td class="Rrule" align="center" valign="bottom">14
</td>
<td class="Rrule" align="center" valign="top">83
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">65
</td>
<td class="Botrule Rrule" align="center" valign="bottom">12
</td>
<td class="Botrule Rrule" align="center" valign="top">57
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">84
</td>
<td class="Rrule" align="center" valign="bottom">6
</td>
<td class="Rrule" align="center" valign="top">89
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">49
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="top">43
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">8
</td>
<td class="Rrule" align="center" valign="bottom">0
</td>
<td class="Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">91
</td>
<td class="Rrule" align="center" valign="bottom">55
</td>
<td class="Rrule" align="center" valign="top">91
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">9
</td>
<td class="Botrule Rrule" align="center" valign="bottom">12
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Febrile</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>**</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">NA<span class="Sup">†</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">34
</td>
<td class="Rrule" align="center" valign="bottom">29
</td>
<td class="Rrule" align="center" valign="top">30
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">10
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Treatment Related Mortality</span></td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">NA<span class="Sup">†</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">6
</td>
<td class="Rrule" align="center" valign="bottom">0
</td>
<td class="Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">34
</td>
<td class="Rrule" align="center" valign="middle">ND<span class="Sup">††</span>
</td>
<td class="Rrule" align="center" valign="top">23
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neurosensory</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
<td class="Rrule" align="center" valign="bottom">14
</td>
<td class="Rrule" align="center" valign="top">29
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neuromotor</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">16
</td>
<td class="Rrule" align="center" valign="bottom">8
</td>
<td class="Rrule" align="center" valign="top">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">20
</td>
<td class="Rrule" align="center" valign="bottom">6
</td>
<td class="Rrule" align="center" valign="top">17
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Any
</td>
<td class="Rrule" align="center" valign="middle">34
</td>
<td class="Rrule" align="center" valign="middle">31
</td>
<td class="Rrule" align="center" valign="middle">31
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Grade 3/4
</td>
<td class="Rrule" align="center" valign="top">5
</td>
<td class="Rrule" align="center" valign="top">4
</td>
<td class="Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Any
</td>
<td class="Rrule" align="center" valign="top">22
</td>
<td class="Rrule" align="center" valign="top">27
</td>
<td class="Rrule" align="center" valign="top">22
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Grade 3/4
</td>
<td class="Rrule" align="center" valign="top">3
</td>
<td class="Rrule" align="center" valign="top">2
</td>
<td class="Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">     Any
</td>
<td class="Rrule" align="center" valign="middle">23
</td>
<td class="Rrule" align="center" valign="middle">6
</td>
<td class="Rrule" align="center" valign="middle">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">56
</td>
<td class="Botrule Rrule" align="center" valign="top">35
</td>
<td class="Botrule Rrule" align="center" valign="top">50
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">53
</td>
<td class="Rrule" align="center" valign="bottom">57
</td>
<td class="Rrule" align="center" valign="bottom">54
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe***
</td>
<td class="Botrule Rrule" align="center" valign="bottom">18
</td>
<td class="Botrule Rrule" align="center" valign="bottom">39
</td>
<td class="Botrule Rrule" align="center" valign="bottom">23
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Any
</td>
<td class="Rrule" align="center" valign="middle">26
</td>
<td class="Rrule" align="center" valign="middle">6
</td>
<td class="Rrule" align="center" valign="middle">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Pulmonary</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="top">41
</td>
<td class="Rrule" align="center" valign="top">49
</td>
<td class="Rrule" align="center" valign="top">45
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="top">29
</td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Any
</td>
<td class="Rrule" align="center" valign="middle">11
</td>
<td class="Rrule" align="center" valign="middle">0
</td>
<td class="Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe***
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="top">6
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe***
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="top">3
</td>
<td class="Rrule" align="center" valign="top">2
</td>
<td class="Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe***
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">   Any
</td>
<td class="Rrule" align="center" valign="middle">6
</td>
<td class="Rrule" align="center" valign="middle">0
</td>
<td class="Rrule" align="center" valign="middle">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">   Severe***
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-6.1.20"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with Docetaxel injection concentrate in chemotherapy-naïve advanced unresectable or metastatic NSCLC</span></p>
<p><a href="#t8">Table 8</a> presents safety data from two arms of an open label, randomized controlled trial (TAX326) that enrolled patients with unresectable stage IIIB or IV non-small cell lung cancer and no history of prior chemotherapy. Adverse reactions were described using the NCI Common Toxicity Criteria except where otherwise noted.
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8 - Adverse Reactions Regardless of Relationship to Treatment in Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer Patients Receiving Docetaxel Injection Concentrate in Combination with Cisplatin
</span></caption>
<col align="left" width="37.667%">
<col align="left" width="33.033%">
<col align="left" width="29.300%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">* Replaces NCI term “Allergy?
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">** COSTART term and grading system
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Rrule Toprule" align="center" valign="top">
<span class="Bold">Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">+ Cisplatin</span></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Vinorelbine 25 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">+</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Cisplatin 100 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=406</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=396</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">91
</td>
<td class="Rrule" align="center" valign="bottom">90
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">74
</td>
<td class="Botrule Rrule" align="center" valign="bottom">78
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">15
</td>
<td class="Rrule" align="center" valign="bottom">15
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">89
</td>
<td class="Rrule" align="center" valign="bottom">94
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
<td class="Botrule Rrule" align="center" valign="bottom">25
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">35
</td>
<td class="Rrule" align="center" valign="bottom">37
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">33
</td>
<td class="Rrule" align="center" valign="bottom">29
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt; 1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span>*</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">12
</td>
<td class="Rrule" align="center" valign="bottom">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt; 1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>**</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">54
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   All severe or life-threatening events
</td>
<td class="Rrule" align="center" valign="bottom">2
</td>
<td class="Rrule" align="center" valign="bottom">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">23
</td>
<td class="Rrule" align="center" valign="bottom">22
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   All severe or life-threatening events
</td>
<td class="Rrule" align="center" valign="bottom">2
</td>
<td class="Rrule" align="center" valign="bottom">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">34
</td>
<td class="Rrule" align="center" valign="bottom">18
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   All severe or life-threatening events
</td>
<td class="Rrule" align="center" valign="bottom">&lt;1
</td>
<td class="Rrule" align="center" valign="bottom">&lt;1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">15
</td>
<td class="Rrule" align="center" valign="bottom">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   All severe or life-threatening events
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neurosensory</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">47
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">4
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Neuromotor</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">19
</td>
<td class="Rrule" align="center" valign="bottom">17
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">16
</td>
<td class="Rrule" align="center" valign="bottom">14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">72
</td>
<td class="Rrule" align="center" valign="bottom">76
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">10
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">55
</td>
<td class="Rrule" align="center" valign="bottom">61
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">16
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">47
</td>
<td class="Rrule" align="center" valign="bottom">25
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">7
</td>
<td class="Botrule Rrule" align="center" valign="bottom">3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></span>**
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
<td class="Rrule" align="center" valign="bottom">40
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   All severe or life-threatening events
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">24
</td>
<td class="Rrule" align="center" valign="bottom">21
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3/4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">75
</td>
<td class="Rrule" align="center" valign="bottom">42
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Grade 3
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>**</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">74
</td>
<td class="Rrule" align="center" valign="bottom">75
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   All severe or life-threatening events
</td>
<td class="Botrule Rrule" align="center" valign="bottom">12
</td>
<td class="Botrule Rrule" align="center" valign="bottom">14
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span>**</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">14
</td>
<td class="Rrule" align="center" valign="bottom">&lt;1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   All severe events
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>**</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">   Any
</td>
<td class="Rrule" align="center" valign="bottom">18
</td>
<td class="Rrule" align="center" valign="bottom">12
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">   All severe events
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;1
</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> within 30 days of last study treatment occurred in 31 patients (7.6%) in the docetaxel+cisplatin arm and 37 patients (9.3%) in the vinorelbine+cisplatin arm. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> within 30 days of last study treatment attributed to study drug occurred in 9 patients (2.2%) in the docetaxel+cisplatin arm and 8 patients (2.0%) in the vinorelbine+cisplatin arm.
</p>
<p>The second comparison in the study, vinorelbine+cisplatin versus docetaxel injection concentrate+carboplatin (which did not demonstrate a superior survival associated with docetaxel injection concentrate, <span class="Italics">[see Clinical Studies (<a href="#s113">14.3</a>)]</span>) demonstrated a higher incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, skin toxicity, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail changes</span> on the docetaxel injection concentrate+carboplatin arm, while a higher incidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, neurosensory toxicity, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> was observed on the vinorelbine+cisplatin arm.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-6.1.21"></a><p></p>
<p class="First"><span class="Underline">Prostate Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-6.1.22"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with Docetaxel injection concentrate in patients with prostate cancer</span></p>
<p>The following data are based on the experience of 332 patients, who were treated with docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> every 3 weeks in combination with prednisone 5 mg orally twice daily (see <a href="#t9">Table 9</a>).
</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9 - Clinically Important Treatment Emergent Adverse Reactions (Regardless of Relationship) in Patients with Prostate Cancer who Received Docetaxel Injection Concentrate in Combination with Prednisone (TAX327)
</span></caption>
<col align="left" width="35.820%">
<col align="left" width="15.160%">
<col align="left" width="16.940%">
<col align="left" width="16.040%">
<col align="left" width="16.040%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">*Related to treatment
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Mitoxantrone 12 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">every 3 weeks +</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">every 3 weeks +</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">prednisone 5 mg twice daily</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">prednisone 5 mg twice daily</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">n=332</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">n=335</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Any</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Grade 3/4</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Any</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Grade 3/4</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">67
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">58
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">41
</td>
<td class="Botrule Rrule" align="center" valign="middle">32
</td>
<td class="Botrule Rrule" align="center" valign="middle">48
</td>
<td class="Botrule Rrule" align="center" valign="middle">22
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">32
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">20
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>*</span></td>
<td class="Rrule" align="center" valign="top">24
</td>
<td class="Rrule" align="center" valign="top">1
</td>
<td class="Rrule" align="center" valign="top">5
</td>
<td class="Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>*
</td>
<td class="Rrule" align="center" valign="top">8
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">3
</td>
<td class="Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span>*
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> Sensory</span></td>
<td class="Botrule Rrule" align="center" valign="middle">30
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> Motor</span></td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">Desquamation</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">65
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Changes</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">30
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">41
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">36
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">32
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">20
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Disturbance</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">18
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">17
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">17
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">15
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cardiac left ventricular function</span></td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">22
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">53
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">35
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">15
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Tearing</span></td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-6.1.23"></a><p></p>
<p class="First"><span class="Underline">Gastric Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-6.1.24"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with Docetaxel injection concentrate in gastric adenocarcinoma</span></p>
<p>Data in the following table are based on the experience of 221 patients with advanced gastric adenocarcinoma and no history of prior chemotherapy for advanced disease, who were treated with docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> in combination with cisplatin and fluorouracil (see <a href="#t10">Table 10</a>).
</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10 - Clinically Important Treatment Emergent Adverse Reactions Regardless of Relationship to Treatment in the Gastric Cancer Study
</span></caption>
<col align="left" width="35.920%">
<col align="left" width="14.720%">
<col align="left" width="16.400%">
<col align="left" width="16.440%">
<col align="left" width="16.520%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">Clinically important treatment emergent adverse reactions were determined based upon frequency, severity, and clinical impact of the adverse reaction.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">*Related to treatment
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">+</span>
</td>
<td class="Rrule Toprule" align="center" colspan="2" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"></td>
<td class="Rrule" align="center" colspan="2" valign="middle">
<span class="Bold">cisplatin 75 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">+</span>
</td>
<td class="Rrule" align="center" colspan="2" valign="middle">
<span class="Bold">Cisplatin 100 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">+</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"></td>
<td class="Rrule" align="center" colspan="2" valign="middle">
<span class="Bold">fluorouracil 750 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule" align="center" colspan="2" valign="middle">
<span class="Bold">fluorouracil 1000 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">n=221</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">n=224</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade 3/4</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade 3/4</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">97
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
<td class="Botrule Rrule" align="center" valign="top">93
</td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">96
</td>
<td class="Botrule Rrule" align="center" valign="top">82
</td>
<td class="Botrule Rrule" align="center" valign="top">83
</td>
<td class="Botrule Rrule" align="center" valign="top">57
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in the absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">36
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">23
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">39
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">29
</td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">23
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>*</span></td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>*</span></td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">63
</td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="top">58
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Neurosensory</span></td>
<td class="Botrule Rrule" align="center" valign="top">38
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Neuromotor</span></td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">67
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">41
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail changes</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Skin desquamation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">73
</td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">76
</td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">67
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">73
</td>
<td class="Botrule Rrule" align="center" valign="top">19
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">51
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">54
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">59
</td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="top">61
</td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">78
</td>
<td class="Botrule Rrule" align="center" valign="top">20
</td>
<td class="Botrule Rrule" align="center" valign="top">50
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">34
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span>/<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>/<span class="product-label-link" type="condition" conceptid="4147218" conceptname="Swallowing painful">odynophagia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>/cramping</span></td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac dysrhythmias</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Tearing</span></td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Altered hearing</span></td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-6.1.25"></a><p></p>
<p class="First"><span class="Underline">Head and Neck Cancer</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-6.1.26"></a><p></p>
<p class="First"><span class="Italics">Combination therapy with Docetaxel injection concentrate in head and neck cancer</span></p>
<p><a href="#t11">Table 11</a> summarizes the safety data obtained from patients that received induction chemotherapy with Docetaxel Injection Concentrate 75 mg/m<span class="Sup">2</span> in combination with cisplatin and fluorouracil followed by radiotherapy (TAX323; 174 patients) or chemoradiotherapy (TAX324; 251 patients). The treatment regimens are described in Section 14.6.
</p>
<a name="t11"></a><table width="100%">
<caption><span>Table 11 – Clinically Important Treatment Emergent Adverse Reactions (Regardless of Relationship) in Patients with SCCHN Receiving Induction Chemotherapy with Docetaxel Injection Concentrate in Combination with Cisplatin and Fluorouracil Followed by Radiotherapy (TAX323) or Chemoradiotherapy (TAX324)
</span></caption>
<col align="left" width="29.178%">
<col align="left" width="9.478%">
<col align="left" width="8.400%">
<col align="left" width="9.244%">
<col align="left" width="9.244%">
<col align="left" width="7.567%">
<col align="left" width="9.244%">
<col align="left" width="8.400%">
<col align="left" width="9.244%">
<tfoot>
<tr class="First"><td align="left" colspan="9" valign="top"><p class="First Footnote">Clinically important treatment emergent adverse reactions based upon frequency, severity, and clinical impact.
</p></td></tr>
<tr><td align="left" colspan="9" valign="top"><p class="First Footnote">*<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span>: grade ≥2 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> concomitant with grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> requiring intravenous antibiotics and/or hospitalization.
</p></td></tr>
<tr><td align="left" colspan="9" valign="top"><p class="First Footnote">**Related to treatment.
</p></td></tr>
<tr class="Last"><td align="left" colspan="9" valign="top"><p class="First Footnote">*** Includes superficial and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">TAX323</span></td>
<td class="Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">TAX324</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">(n=355)</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">(n=494)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Docetaxel Injection Concentrate arm</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold"><br>Comparator arm</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Docetaxel Injection Concentrate arm</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold"><br>Comparator arm</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">(n=174)</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">(n=181)</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">(n=251)</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">(n=243)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Any</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Grade</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center" valign="top">%
</td>
<td class="Rrule" align="center" valign="top">3/4
</td>
<td class="Rrule" align="center" valign="top">%
</td>
<td class="Rrule" align="center" valign="top">3/4
</td>
<td class="Rrule" align="center" valign="top">%
</td>
<td class="Rrule" align="center" valign="top">3/4
</td>
<td class="Rrule" align="center" valign="top">%
</td>
<td class="Rrule" align="center" valign="top">3/4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">(by Body System)
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">93
</td>
<td class="Botrule Rrule" align="center" valign="middle">76
</td>
<td class="Botrule Rrule" align="center" valign="middle">87
</td>
<td class="Botrule Rrule" align="center" valign="middle">53
</td>
<td class="Botrule Rrule" align="center" valign="middle">95
</td>
<td class="Botrule Rrule" align="center" valign="middle">84
</td>
<td class="Botrule Rrule" align="center" valign="middle">84
</td>
<td class="Botrule Rrule" align="center" valign="middle">56
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">89
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">88
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">90
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">86
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">24
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">47
</td>
<td class="Botrule Rrule" align="center" valign="middle">18
</td>
<td class="Botrule Rrule" align="center" valign="middle">28
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">31
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">26
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">23
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">28
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span>*</span></td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">N/A
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">17
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">20
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">41
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">38
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">61
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">56
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in the absence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">32
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">37
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">30
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">28
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">21
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">27
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>**</span></td>
<td class="Rrule" align="center" valign="top">20
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">14
</td>
<td class="Rrule" align="center" valign="top">1
</td>
<td class="Rrule" align="center" valign="top">13
</td>
<td class="Rrule" align="center" valign="top">1
</td>
<td class="Rrule" align="center" valign="top">7
</td>
<td class="Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> only</span></td>
<td class="Rrule" align="center" valign="top">13
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">7
</td>
<td class="Rrule" align="center" valign="top">0
</td>
<td class="Rrule" align="center" valign="top">12
</td>
<td class="Rrule" align="center" valign="top">1
</td>
<td class="Rrule" align="center" valign="top">6
</td>
<td class="Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> only</span></td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">15
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neurosensory</span></td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Altered hearing</span></td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">19
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Neuromotor</span></td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">81
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
<td class="Botrule Rrule" align="center" valign="middle">43
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">68
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">44
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">20
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">Desquamation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">47
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">51
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">77
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
<td class="Botrule Rrule" align="center" valign="middle">80
</td>
<td class="Botrule Rrule" align="center" valign="middle">14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">43
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">47
</td>
<td class="Botrule Rrule" align="center" valign="middle">11
</td>
<td class="Botrule Rrule" align="center" valign="middle">66
</td>
<td class="Botrule Rrule" align="center" valign="middle">21
</td>
<td class="Botrule Rrule" align="center" valign="middle">68
</td>
<td class="Botrule Rrule" align="center" valign="middle">27
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">39
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">56
</td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">63
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">33
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">24
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">48
</td>
<td class="Botrule Rrule" align="center" valign="middle">7
</td>
<td class="Botrule Rrule" align="center" valign="middle">40
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">17
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">27
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">38
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">25
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">40
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
<td class="Botrule Rrule" align="center" valign="middle">34
</td>
<td class="Botrule Rrule" align="center" valign="middle">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span>/<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>/ <span class="product-label-link" type="condition" conceptid="4147218" conceptname="Swallowing painful">Odynophagia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">18
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">25
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">26
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Taste, sense of smell altered</span></td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">20
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">17
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>/cramping</span></td>
<td class="Botrule Rrule" align="center" valign="middle">8
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">9
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">15
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">10
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">13
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Cardiac dysrhythmia</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Venous***</span></td>
<td class="Botrule Rrule" align="center" valign="middle">3
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">6
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" valign="middle">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemia myocardial</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Tearing</span></td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">2
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">1
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.4
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experiences
</h2>
<p class="First">The following adverse reactions have been identified from clinical trials and/or post-marketing surveillance. Because they are reported from a population of unknown size, precise estimates of frequency cannot be made.
</p>
<p><span class="Bold">Body as a whole:</span> diffuse <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, radiation <span class="product-label-link" type="condition" conceptid="4033685" conceptname="Radiation recall syndrome">recall phenomenon</span>.
</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, ECG abnormalities, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.
</p>
<p><span class="Bold">Cutaneous:</span> very rare cases of <span class="product-label-link" type="condition" conceptid="4324123" conceptname="Cutaneous lupus erythematosus">cutaneous lupus erythematosus</span> and rare cases of <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span> such as <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">Scleroderma</span>-like changes usually preceded by peripheral <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>. In some cases multiple factors may have contributed to the development of these effects. Severe <span class="product-label-link" type="condition" conceptid="4033054" conceptname="Acral erythema">hand and foot syndrome</span> has been reported.
</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic enterocolitis</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> as a consequence to gastrointestinal events have been reported.
</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated intravascular coagulation</span> (DIC), often in association with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiorgan failure</span>, has been reported. Cases of <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> and myelodysplasic syndrome have been reported in association with docetaxel injection concentrate when used in combination with other chemotherapy agents and/or radiotherapy.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been reported. Very rarely these cases resulted in a fatal outcome in patients who received premedication.
</p>
<p><span class="Bold">Hepatic:</span> rare cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, sometimes fatal primarily in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span>, have been reported.
</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, rare cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or transient <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> have been observed, sometimes appearing during the infusion of the drug.
</p>
<p><span class="Bold">Ophthalmologic:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> or <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Excessive tearing which may be attributable to <span class="product-label-link" type="condition" conceptid="439026" conceptname="Stenosis of lacrimal sac">lacrimal duct obstruction</span> has been reported. Rare cases of transient <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (flashes, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">flashing lights</span>, scotomata) typically occurring during drug infusion and in association with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported. These were reversible upon discontinuation of the infusion.
</p>
<p><span class="Bold">Hearing:</span> rare cases of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, hearing disorders and/or <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> have been reported, including cases associated with other ototoxic drugs.
</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">acute pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span>. <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">Pulmonary fibrosis</span> has been rarely reported. Rare cases of <span class="product-label-link" type="condition" conceptid="4221865" conceptname="Radiation pneumonitis">radiation pneumonitis</span> have been reported in patients receiving concomitant radiotherapy.
</p>
<p><span class="Bold">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have been reported, the majority of these cases were associated with concomitant nephrotoxic drugs.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s78"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS
</h1>
<p class="First">Docetaxel is a CYP3A4 substrate. <span class="Italics">In vitro</span> studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.
</p>
<p><span class="Italics">In vivo</span> studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of Docetaxel Injection Concentrate and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with Docetaxel Injection Concentrate, close monitoring for toxicity and a Docetaxel Injection Concentrate dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>) and Clinical Pharmacology (<a href="#s95">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s79"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s80"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category D <span class="Italics">[see ‘<a href="#s37">Warnings and Precautions</a>’ section]</span></p>
<p>Based on its mechanism of action and findings in animals, docetaxel injection concentrate can cause fetal harm when administered to a pregnant woman. If docetaxel injection concentrate is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with docetaxel injection concentrate.
</p>
<p>Docetaxel injection concentrate can cause fetal harm when administered to a pregnant woman. Studies in both rats and rabbits at doses ≥0.3 and 0.03 mg/kg/day, respectively (about 1/50 and 1/300 the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis), administered during the period of organogenesis, have shown that docetaxel injection concentrate is embryotoxic and fetotoxic (characterized by intrauterine mortality, increased resorption, reduced fetal weight, and fetal ossification delay). The doses indicated above also caused maternal toxicity.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s81"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether docetaxel is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from docetaxel injection concentrate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s82"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of docetaxel injection concentrate in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s83"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Italics">Non-Small Cell Lung Cancer</span></p>
<p>In a study conducted in chemotherapy-naïve patients with NSCLC (TAX326), 148 patients (36%) in the docetaxel injection concentrate+cisplatin group were 65 years of age or greater. There were 128 patients (32%) in the vinorelbine+cisplatin group 65 years of age or greater. In the docetaxel injection concentrate+cisplatin group, patients less than 65 years of age had a median survival of 10.3 months (95% CI: 9.1 months, 11.8 months) and patients 65 years or older had a median survival of 12.1 months (95% CI: 9.3 months, 14 months). In patients 65 years of age or greater treated with docetaxel injection concentrate+cisplatin, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (55%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (39%) and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (28%) were observed more frequently than in the vinorelbine+cisplatin group (<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 24%, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> 20%, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> 20%). Patients treated with docetaxel injection concentrate+cisplatin who were 65 years of age or greater were more likely to experience <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (55%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (42%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (39%) and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (28%) compared to patients less than the age of 65 administered the same treatment (43%, 31%, 31% and 21%, respectively).
</p>
<p>When docetaxel injection concentrate was combined with carboplatin for the treatment of chemotherapy-naïve, advanced non-small cell lung carcinoma, patients 65 years of age or greater (28%) experienced higher frequency of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> compared to similar patients treated with docetaxel injection concentrate+cisplatin, and a higher frequency of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> than elderly patients treated with vinorelbine+cisplatin.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Italics Underline">Prostate Cancer</span></p>
<p>Of the 333 patients treated with docetaxel injection concentrate every three weeks plus prednisone in the prostate cancer study (TAX327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years. In patients treated with docetaxel injection concentrate every three weeks, the following treatment emergent adverse reactions occurred at rates ≥10% higher in patients 65 years of age or greater compared to younger patients: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (71% vs. 59%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (37% vs. 24%), <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail changes</span> (34% vs. 23%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (21% vs. 10%), <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (15% vs. 5%) respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-8.4.3"></a><p></p>
<p class="First"><span class="Italics Underline">Breast Cancer</span></p>
<p>In the adjuvant breast cancer trial (TAX316), docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 (6%) were 65 years of age or greater. The number of elderly patients who received this regimen was not sufficient to determine whether there were differences in safety and efficacy between elderly and younger patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-8.4.4"></a><p></p>
<p class="First"><span class="Italics Underline">Gastric Cancer</span></p>
<p>Among the 221 patients treated with docetaxel injection concentrate in combination with cisplatin and fluorouracil in the gastric cancer study, 54 were 65 years of age or older and 2 patients were older than 75 years. In this study, the number of patients who were 65 years of age or older was insufficient to determine whether they respond differently from younger patients. However, the incidence of serious adverse reactions was higher in the elderly patients compared to younger patients. The incidence of the following adverse reactions (all grades, regardless of relationship): <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>/neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurred at rates ≥10% higher in patients who were 65 years of age or older compared to younger patients. Elderly patients treated with TCF should be closely monitored.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-8.4.5"></a><p></p>
<p class="First"><span class="Italics Underline">Head and Neck Cancer</span></p>
<p>Among the 174 and 251 patients who received the induction treatment with docetaxel injection concentrate in combination with cisplatin and fluorouracil (TPF) for SCCHN in the TAX323 and TAX324 studies, 18 (10%) and 32 (13%) of the patients were 65 years of age or older, respectively.
</p>
<p>These clinical studies of docetaxel injection concentrate in combination with cisplatin and fluorouracil in patients with SCCHN did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience with this treatment regimen has not identified differences in responses between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Patients with bilirubin &gt;ULN should not receive Docetaxel Injection Concentrate. Also, patients with AST and/or ALT &gt;1.5 x ULN concomitant with alkaline phosphatase &gt;2.5 x ULN should not receive Docetaxel Injection Concentrate <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s41">5.2</a>), Clinical Pharmacology (<a href="#s95">12.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s90"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE
</h1>
<p class="First">There is no known antidote for docetaxel injection concentrate overdosage. In case of overdosage, the patient should be kept in a specialized unit where vital functions can be closely monitored. Anticipated complications of overdosage include: bone marrow suppression, peripheral <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>. Patients should receive therapeutic G-CSF as soon as possible after discovery of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Other appropriate symptomatic measures should be taken, as needed.
</p>
<p>In two reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, one patient received 150 mg/m<span class="Sup">2</span> and the other received 200 mg/m<span class="Sup">2</span> as 1-hour infusions. Both patients experienced severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, mild <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, cutaneous reactions, and mild <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and recovered without incident.
</p>
<p>In mice, lethality was observed following single intravenous doses that were ≥154 mg/kg (about 4.5 times the human dose of 100 mg/m<span class="Sup">2</span> on a mg/m<span class="Sup">2</span> basis); <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> associated with <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, non-extension of hind limbs, and myelin degeneration was observed in mice at 48 mg/kg (about 1.5 times the human dose of 100 mg/m<span class="Sup">2</span> basis). In male and female rats, lethality was observed at a dose of 20 mg/kg (comparable to the human dose of 100 mg/m<span class="Sup">2</span> on a mg/m<span class="Sup">2</span> basis) and was associated with abnormal mitosis and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of multiple organs.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s91"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION
</h1>
<p class="First">Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-<span class="Italics">tert</span>-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, anhydrous. Docetaxel has the following structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-01.jpg">
</div>
<p>Docetaxel is a white to almost-white powder with an empirical formula of C<span class="Sub">43</span>H<span class="Sub">53</span>NO<span class="Sub">14</span>, and a molecular weight of 807.88. It is highly lipophilic and practically insoluble in water.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold Underline">One-vial Docetaxel Injection Concentrate</span></p>
<p>Docetaxel injection concentrate is a sterile, non-pyrogenic, clear, viscous, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution, without macroscopic particles in solution at 20 mg/mL docetaxel concentration.
</p>
<p>Each mL contains 20 mg docetaxel, citric acid anhydrous (6 mg), kollidon 12 PF (povidone P12) (100 mg), polysorbate 80 (424 mg) and ethanol  (400 mg/ mL).
</p>
<p>Docetaxel injection concentrate is available in single use vials containing 20 mg (1 mL), 80 mg (4 mL) or 140 mg (7 mL) docetaxel.
</p>
<p>Docetaxel injection concentrate requires NO prior dilution with a diluent and is ready to add to the infusion solution.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s93"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s94"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the inhibition of mitosis in cells. Docetaxel's binding to microtubules does not alter the number of protofilaments in the bound microtubules, a feature which differs from most spindle poisons currently in clinical use.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s95"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Human Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption:</span> The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20 mg/m<span class="Sup">2</span> to 115 mg/m<span class="Sup">2</span> in phase 1 studies. The area under the curve (AUC) was dose proportional following doses of 70 mg/m<span class="Sup">2</span> to 115 mg/m<span class="Sup">2</span> with infusion times of 1 to 2 hours. Docetaxel's pharmacokinetic profile is consistent with a three-compartment pharmacokinetic model, with half-lives for the α, β, and γ phases of 4 min, 36 min, and 11.1 hr, respectively. Mean total body clearance was 21 L/h/m<span class="Sup">2</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span> The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment. Mean steady state volume of distribution was 113 L. <span class="Italics">In vitro</span> studies showed that docetaxel is about 94% protein bound, mainly to α1-acid glycoprotein, albumin, and lipoproteins. In three cancer patients, the <span class="Italics">in vitro</span> binding to plasma proteins was found to be approximately 97%. Dexamethasone does not affect the protein binding of docetaxel.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism:
</span><span class="Italics">In vitro</span> drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme, and its metabolism may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4 <span class="Italics">[see Drug Interactions (<a href="#s78">7</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s99"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Bold">Elimination:</span> A study of <span class="Sup">14</span>C-docetaxel was conducted in three cancer patients. Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the <span class="Italics">tert</span>-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in feces is excreted during the first 48 hours as 1 major and 3 minor metabolites with very small amounts (less than 8%) of unchanged drug.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s100"></a><a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Bold">Effect of Age:</span> A population pharmacokinetic analysis was carried out after docetaxel treatment of 535 patients dosed at 100 mg/m<span class="Sup">2</span>. Pharmacokinetic parameters estimated by this analysis were very close to those estimated from phase 1 studies. The pharmacokinetics of docetaxel were not influenced by age.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s101"></a><a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Bold">Effect of Gender:</span> The population pharmacokinetics analysis described above also indicated that gender did not influence the pharmacokinetics of docetaxel.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s102"></a><a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The population pharmacokinetic analysis described above indicated that in patients with clinical chemistry data suggestive of mild to moderate liver impairment (AST and/or ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN), total body clearance was lowered by an average of 27%, resulting in a 38% increase in systemic exposure (AUC). This average, however, includes a substantial range and there is, at present, no measurement that would allow recommendation for dose adjustment in such patients. Patients with combined abnormalities of transaminase and alkaline phosphatase should not be treated with Docetaxel Injection Concentrate. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.2</a>) and Use in Specific Populations (<a href="#s89">8.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s103"></a><a name="section-11.2.8"></a><p></p>
<p class="First"><span class="Bold">Effect of Race:</span> Mean total body clearance for Japanese patients dosed at the range of 10 mg/m<span class="Sup">2</span> to 90 mg/m<span class="Sup">2</span> was similar to that of European/American populations dosed at 100 mg/m<span class="Sup">2</span>, suggesting no significant difference in the elimination of docetaxel in the two populations.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s104"></a><a name="section-11.2.9"></a><p></p>
<p class="First"><span class="Bold">Effect of Ketoconazole:</span> The effect of ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics of docetaxel was investigated in 7 cancer patients. Patients were randomized to receive either docetaxel (100 mg/m<span class="Sup">2</span> intravenous) alone or docetaxel (10 mg/m<span class="Sup">2</span> intravenous) in combination with ketoconazole (200 mg orally once daily for 3 days) in a crossover design with a 3-week washout period. The results of this study indicated that the mean dose-normalized AUC of docetaxel was increased 2.2-fold and its clearance was reduced by 49% when docetaxel was co-administered with ketoconazole <span class="Italics">[see Dosage and Administration (<a href="#s16">2.7</a>) and Drug Interactions (<a href="#s78">7</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s105"></a><a name="section-11.2.10"></a><p></p>
<p class="First"><span class="Bold">Effect of Combination Therapies:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Dexamethasone:</span> Docetaxel total body clearance was not modified by pretreatment with dexamethasone.
</li>
<li>
<span class="Bold">Cisplatin:</span> Clearance of docetaxel in combination therapy with cisplatin was similar to that previously observed following monotherapy with docetaxel. The pharmacokinetic profile of cisplatin in combination therapy with docetaxel was similar to that observed with cisplatin alone.
</li>
<li>
<span class="Bold">Cisplatin and Fluorouracil:</span> The combined administration of docetaxel, cisplatin and fluorouracil in 12 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> had no influence on the pharmacokinetics of each individual drug.
</li>
<li>
<span class="Bold">Prednisone:</span> A population pharmacokinetic analysis of plasma data from 40 patients with hormone-refractory metastatic prostate cancer indicated that docetaxel systemic clearance in combination with prednisone is similar to that observed following administration of docetaxel alone.
</li>
<li>
<span class="Bold">Cyclophosphamide and Doxorubicin:</span> A study was conducted in 30 patients with advanced breast cancer to determine the potential for drug-drug-interactions between docetaxel (75 mg/m<span class="Sup">2</span>), doxorubicin (50 mg/m<span class="Sup">2</span>), and cyclophosphamide (500 mg/m<span class="Sup">2</span>) when administered in combination. The coadministration of docetaxel had no effect on the pharmacokinetics of doxorubicin and cyclophosphamide when the three drugs were given in combination compared to coadministration of doxorubicin and cyclophosphamide only. In addition, doxorubicin and cyclophosphamide had no effect on docetaxel plasma clearance when the three drugs were given in combination compared to historical data for docetaxel monotherapy.
</li>
</ul>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s106"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s107"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenicity studies with docetaxel have not been performed.
</p>
<p>Docetaxel was clastogenic in the <span class="Italics">in vitro</span> chromosome aberration test in CHO-K<span class="Sub">1</span> cells and in the <span class="Italics">in vivo</span> micronucleus test in mice administered doses of 0.39 to 1.56 mg/kg (about 1/60<span class="Sup">th</span> to 1/15<span class="Sup">th</span> the recommended human dose on a mg/m<span class="Sup">2</span> basis). Docetaxel was not mutagenic in the Ames test or the CHO/HGPRT gene mutation assays.
</p>
<p>Docetaxel did not reduce fertility in rats when administered in multiple intravenous doses of up to 0.3 mg/kg (about 1/50<span class="Sup">th</span> the recommended human dose on a mg/m<span class="Sup">2</span> basis), but decreased testicular weights were reported. This correlates with findings of a 10-cycle toxicity study (dosing once every 21 days for 6 months) in rats and dogs in which <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> or degeneration was observed at intravenous doses of 5 mg/kg in rats and 0.375 mg/kg in dogs (about 1/3<span class="Sup">rd</span> and 1/15<span class="Sup">th</span> the recommended human dose on a mg/m<span class="Sup">2</span> basis, respectively). An increased frequency of dosing in rats produced similar effects at lower dose levels.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s108"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s109"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Locally Advanced or Metastatic Breast Cancer
</h2>
<p class="First">The efficacy and safety of docetaxel injection concentrate have been evaluated in locally advanced or metastatic breast cancer after failure of previous chemotherapy (alkylating agent-containing regimens or anthracycline-containing regimens).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s110"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Randomized Trials</span></p>
<p>In one randomized trial, patients with a history of prior treatment with an anthracycline-containing regimen were assigned to treatment with docetaxel injection concentrate (100 mg/m<span class="Sup">2</span> every 3 weeks) or the combination of mitomycin (12 mg/m<span class="Sup">2</span> every 6 weeks) and vinblastine (6 mg/m<span class="Sup">2</span> every 3 weeks). Two hundred three patients were randomized to docetaxel injection concentrate and 189 to the comparator arm. Most patients had received prior chemotherapy for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>; only 27 patients on the docetaxel injection concentrate arm and 33 patients on the comparator arm entered the study following relapse after adjuvant therapy. Three-quarters of patients had measurable, visceral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. The primary endpoint was time to progression. The following table summarizes the study results (See <a href="#t12">Table 12</a>).
</p>
<a name="t12"></a><table width="100%">
<caption><span>Table 12 - Efficacy of Docetaxel Injection Concentrate in the Treatment of Breast Cancer Patients Previously Treated with an Anthracycline-Containing Regimen (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="31.286%">
<col align="left" width="22.424%">
<col align="left" width="10%">
<col align="left" width="22.905%">
<col align="left" width="22.905%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">*For the risk ratio, a value less than 1.00 favors docetaxel.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Docetaxel</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Mitomycin/</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Vinblastine</span></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">(n=203)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(n=189)</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Survival
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">11.4 months
</td>
<td class="Botrule Rrule" align="center" valign="top">8.7 months
</td>
<td class="Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Risk Ratio*, Mortality
</td>
<td class="Rrule" align="center" colspan="3" valign="bottom"></td>
<td class="Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(Docetaxel: Control)
</td>
<td class="Rrule" align="center" colspan="3" valign="bottom">0.73
</td>
<td class="Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="3" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle">p=0.01
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="3" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle">Log Rank
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI (Risk Ratio)
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom">0.58 to 0.93
</td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Time to Progression
</td>
<td class="Botrule Rrule" align="center" valign="top">4.3 months
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">2.5 months
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Risk Ratio*, Progression
</td>
<td class="Rrule" align="center" colspan="3" valign="top"></td>
<td class="Rrule" align="center" valign="top">p=0.01
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(Docetaxel: Control)
</td>
<td class="Rrule" align="center" colspan="3" valign="top">0.75
</td>
<td class="Rrule" align="center" valign="top">Log Rank
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="3" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="3" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI (Risk Ratio)
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">0.61 to 0.94
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Overall Response Rate
</td>
<td class="Rrule" align="center" colspan="2" valign="top">28.1%
</td>
<td class="Rrule" align="center" valign="top">9.5%
</td>
<td class="Rrule" align="center" valign="top">p&lt;0.0001
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Complete Response Rate
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">3.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">Chi Square
</td>
</tr>
</tbody>
</table>
<p>In a second randomized trial, patients previously treated with an alkylating-containing regimen were assigned to treatment with docetaxel injection concentrate (100 mg/m<span class="Sup">2</span>) or doxorubicin (75 mg/m<span class="Sup">2</span>) every 3 weeks. One hundred sixty-one patients were randomized to docetaxel injection concentrate and 165 patients to doxorubicin. Approximately one-half of patients had received prior chemotherapy for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>, and one-half entered the study following relapse after adjuvant therapy. Three-quarters of patients had measurable, visceral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. The primary endpoint was time to progression. The study results are summarized below (See <a href="#t13">Table 13</a>).
</p>
<a name="t13"></a><table width="100%">
<caption><span>Table 13 - Efficacy of Docetaxel Injection Concentrate in the Treatment of Breast Cancer Patients Previously Treated with an Alkylating-Containing Regimen (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="30.700%">
<col align="left" width="20.975%">
<col align="left" width="24.175%">
<col align="left" width="24.150%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">*For the risk ratio, a value less than 1.00 favors docetaxel.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Efficacy Parameter</span></td>
<td class="Rrule Toprule" align="center" valign="middle"><span class="Bold">Docetaxel</span></td>
<td class="Rrule Toprule" align="center" valign="middle"><span class="Bold">Doxorubicin</span></td>
<td class="Rrule Toprule" align="center" valign="middle"><span class="Bold">p-value</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(n=161)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(n=165)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Survival
</td>
<td class="Botrule Rrule" align="center" valign="top">14.7 months
</td>
<td class="Botrule Rrule" align="center" valign="top">14.3 months
</td>
<td class="Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Risk Ratio*, Mortality
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(Docetaxel: Control)
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.89
</td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle">p=0.39
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle">Log Rank
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI (Risk Ratio)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">0.68 to 1.16
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Time to Progression
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6.5 months
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5.3 months
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Risk Ratio*, Progression
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(Docetaxel: Control)
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.93
</td>
<td class="Rrule" align="center" valign="middle">p=0.45
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle">Log Rank
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI (Risk Ratio)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">0.71 to 1.16
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Overall Response Rate
</td>
<td class="Rrule" align="center" valign="top">45.3%
</td>
<td class="Rrule" align="center" valign="top">29.7%
</td>
<td class="Rrule" align="center" valign="top">p=0.004
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Complete Response Rate
</td>
<td class="Botrule Rrule" align="center" valign="top">6.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">4.2%
</td>
<td class="Botrule Rrule" align="center" valign="top">Chi Square
</td>
</tr>
</tbody>
</table>
<p>In another multicenter open-label, randomized trial (TAX313), in the treatment of patients with advanced breast cancer who progressed or relapsed after one prior chemotherapy regimen, 527 patients were randomized to receive docetaxel injection concentrate monotherapy 60 mg/m<span class="Sup">2</span> (n=151), 75 mg/m<span class="Sup">2</span> (n=188) or 100 mg/m<span class="Sup">2</span> (n=188). In this trial, 94% of patients had <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> and 79% had received prior anthracycline therapy. Response rate was the primary endpoint.
</p>
<p>Response rates increased with docetaxel injection concentrate dose: 19.9% for the 60 mg/m<span class="Sup">2</span> group compared to 22.3% for the 75 mg/m<span class="Sup">2</span> and 29.8% for the 100 mg/m<span class="Sup">2</span> group; pair-wise comparison between the 60 mg/m<span class="Sup">2</span> and 100 mg/m<span class="Sup">2</span> groups was statistically significant (p=0.037).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s111"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Single Arm Studies</span></p>
<p>Docetaxel injection concentrate at a dose of 100 mg/m<span class="Sup">2</span> was studied in six single arm studies involving a total of 309 patients with metastatic breast cancer in whom previous chemotherapy had failed. Among these, 190 patients had anthracycline-resistant breast cancer, defined as progression during an anthracycline-containing chemotherapy regimen for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>, or relapse during an anthracycline-containing adjuvant regimen. In anthracycline-resistant patients, the overall response rate was 37.9% (72/190; 95% C.I.: 31.0 to 44.8) and the complete response rate was 2.1%.
</p>
<p>Docetaxel injection concentrate was also studied in three single arm Japanese studies at a dose of 60 mg/m<span class="Sup">2</span>, in 174 patients who had received prior chemotherapy for locally advanced or metastatic breast cancer. Among 26 patients whose best response to an anthracycline had been progression, the response rate was 34.6% (95% C.I.: 17.2 to 55.7), similar to the response rate in single arm studies of 100 mg/m<span class="Sup">2</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s112"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Adjuvant Treatment of Breast Cancer
</h2>
<p class="First">A multicenter, open-label, randomized trial (TAX316) evaluated the efficacy and safety of docetaxel injection concentrate for the adjuvant treatment of patients with axillary-node-positive breast cancer and no evidence of distant <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. After stratification according to the number of positive lymph nodes (1 to 3, 4+), 1491 patients were randomized to receive either docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> administered 1-hour after doxorubicin 50 mg/m<span class="Sup">2</span> and cyclophosphamide 500 mg/m<span class="Sup">2</span> (TAC arm), or doxorubicin 50 mg/m<span class="Sup">2</span> followed by fluorouracil 500 mg/m<span class="Sup">2</span> and cyclosphosphamide 500 mg/m<span class="Sup">2</span> (FAC arm). Both regimens were administered every 3 weeks for 6 cycles. Docetaxel injection concentrate was administered as a 1-hour infusion; all other drugs were given as intravenous bolus on day 1. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69% of patients who received TAC and 72% of patients who received FAC.
</p>
<p>Results from a second interim analysis (median follow-up 55 months) are as follows: In study TAX316, the docetaxel-containing combination regimen TAC showed significantly longer disease-free survival (DFS) than FAC (hazard ratio=0.74; 2-sided 95% CI=0.60, 0.92, stratified log rank p=0.0047). The primary endpoint, disease-free survival, included local and distant recurrences, contralateral breast cancer and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> from any cause. The overall reduction in risk of relapse was 25.7% for TAC-treated patients. (See <a href="#fig1">Figure 1</a>).
</p>
<p>At the time of this interim analysis, based on 219 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, overall survival was longer for TAC than FAC (hazard ratio=0.69, 2-sided 95% CI=0.53, 0.90). (See <a href="#fig2">Figure 2</a>). There will be further analysis at the time survival data mature.<br><br></p>
<p class="MultiMediaCaption"><a name="fig1"></a><span class="Bold">Figure 1 - TAX316 Disease Free Survival K-M curve</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-02.jpg">
</div>
<p class="MultiMediaCaption"><a name="fig2"></a><span class="Bold">Figure 2 - TAX316 Overall Survival K-M Curve</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-03.jpg">
</div>
<p>The following table describes the results of subgroup analyses for DFS and OS (See <a href="#t14">Table 14</a>).
</p>
<a name="t14"></a><table width="100%">
<caption><span>Table 14 - Subset Analyses-Adjuvant Breast Cancer Study
</span></caption>
<col align="left" width="20.963%">
<col align="left" width="15.531%">
<col align="left" width="15.781%">
<col align="left" width="15.231%">
<col align="left" width="16.547%">
<col align="left" width="15.947%">
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top"><p class="First Footnote">*a hazard ratio of less than 1 indicates that TAC is associated with a longer disease free survival or overall survival compared to FAC.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Disease Free Survival</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Overall Survival</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Patient subset</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Number of</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Hazard</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">95% CI</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Hazard</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">95% CI</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">patients</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">ratio*</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">ratio*</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">No. of positive nodes</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Overall
</td>
<td class="Rrule" align="center" valign="bottom">744
</td>
<td class="Rrule" align="center" valign="bottom">0.74
</td>
<td class="Rrule" align="center" valign="bottom">(0.60, 0.92)
</td>
<td class="Rrule" align="center" valign="bottom">0.69
</td>
<td class="Rrule" align="center" valign="bottom">(0.53, 0.90)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">1 to 3
</td>
<td class="Rrule" align="center" valign="top">467
</td>
<td class="Rrule" align="center" valign="top">0.64
</td>
<td class="Rrule" align="center" valign="top">(0.47, 0.87)
</td>
<td class="Rrule" align="center" valign="top">0.45
</td>
<td class="Rrule" align="center" valign="top">(0.29, 0.70)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">4+
</td>
<td class="Botrule Rrule" align="center" valign="top">277
</td>
<td class="Botrule Rrule" align="center" valign="top">0.84
</td>
<td class="Botrule Rrule" align="center" valign="top">(0.63, 1.12)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.93
</td>
<td class="Botrule Rrule" align="center" valign="top">(0.66, 1.32)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Receptor status</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Positive
</td>
<td class="Rrule" align="center" valign="bottom">566
</td>
<td class="Rrule" align="center" valign="bottom">0.76
</td>
<td class="Rrule" align="center" valign="bottom">(0.59, 0.98)
</td>
<td class="Rrule" align="center" valign="bottom">0.69
</td>
<td class="Rrule" align="center" valign="bottom">(0.48, 0.99)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Negative
</td>
<td class="Botrule Rrule" align="center" valign="bottom">178
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.68
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(0.48, 0.97)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.66
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(0.44, 0.98)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s113"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Non-Small Cell Lung Cancer (NSCLC)
</h2>
<p class="First">The efficacy and safety of docetaxel injection concentrate has been evaluated in patients with unresectable, locally advanced or metastatic non-small cell lung cancer whose disease has failed prior platinum-based chemotherapy or in patients who are chemotherapy-naïve.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s114"></a><a name="section-13.3.1"></a><p></p>
<p class="First"><span class="Underline">Monotherapy with Docetaxel Injection Concentrate for NSCLC Previously Treated with Platinum-Based Chemotherapy</span></p>
<p>Two randomized, controlled trials established that a docetaxel injection concentrate dose of 75 mg/m<span class="Sup">2</span> was tolerable and yielded a favorable outcome in patients previously treated with platinum-based chemotherapy (see below). Docetaxel injection concentrate at a dose of 100 mg/m<span class="Sup">2</span>, however, was associated with unacceptable hematologic toxicity, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and treatment-related mortality and this dose should not be used <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Dosage and Administration (<a href="#s16">2.7</a>), Warnings and Precautions (<a href="#s42">5.3</a>)]</span>.
</p>
<p>One trial (TAX317), randomized patients with locally advanced or metastatic non-small cell lung cancer, a history of prior platinum-based chemotherapy, no history of taxane exposure, and an ECOG performance status ≤2 to docetaxel injection concentrate or best supportive care. The primary endpoint of the study was survival. Patients were initially randomized to docetaxel injection concentrate 100 mg/m<span class="Sup">2</span> or best supportive care, but early toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at this dose led to a dose reduction to docetaxel injection concentrate 75 mg/m<span class="Sup">2</span>. A total of 104 patients were randomized in this amended study to either docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> or best supportive care.
</p>
<p>In a second randomized trial (TAX320), 373 patients with locally advanced or metastatic non-small cell lung cancer, a history of prior platinum-based chemotherapy, and an ECOG performance status ≤2 were randomized to docetaxel injection concentrate 75 mg/m<span class="Sup">2</span>, docetaxel injection concentrate 100 mg/m<span class="Sup">2</span> and a treatment in which the investigator chose either vinorelbine 30 mg/m<span class="Sup">2</span> days 1, 8, and 15 repeated every 3 weeks or ifosfamide 2 g/m<span class="Sup">2</span> days 1 to 3 repeated every 3 weeks. Forty percent of the patients in this study had a history of prior paclitaxel exposure. The primary endpoint was survival in both trials. The efficacy data for the docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> arm and the comparator arms are summarized in <a href="#t15">Table 15</a> and <a href="#fig3">Figures 3</a> and <a href="#fig4">4</a> showing the survival curves for the two studies.
</p>
<a name="t15"></a><table width="100%">
<caption><span>Table 15 - Efficacy of Docetaxel Injection Concentrate in the Treatment of Non-Small Cell Lung Cancer Patients Previously Treated with a Platinum-Based Chemotherapy Regimen (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="31.286%">
<col align="left" width="17.163%">
<col align="left" width="17.163%">
<col align="left" width="17.163%">
<col align="left" width="17.223%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Vinorelbine/Ifosfamide
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">** p≤0.05; <span class="Sup">†</span> uncorrected for multiple comparisons; <span class="Sup">††</span> a value less than 1.00 favors docetaxel.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">TAX317</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">TAX320</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Docetaxel</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Best</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Docetaxel</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Control</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Supportive</span></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">75 mg/m</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">(V/I*)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=55</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Care</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=125</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">n=123</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=49</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Overall Survival
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Log-rank Test
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">p=0.01
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">p=0.13
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Risk Ratio<span class="Sup">††</span>, Mortality
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
<td class="Rrule" align="center" colspan="2" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(Docetaxel: Control)
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.56
</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.82
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI (Risk Ratio)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">(0.35, 0.88)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">(0.63, 1.06)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median Survival
</td>
<td class="Rrule" align="center" valign="top">7.5 months**
</td>
<td class="Rrule" align="center" valign="top">4.6 months
</td>
<td class="Rrule" align="center" valign="top">5.7 months
</td>
<td class="Rrule" align="center" valign="top">5.6 months
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Botrule Rrule" align="center" valign="top">(5.5, 12.8)
</td>
<td class="Botrule Rrule" align="center" valign="top">(3.7, 6.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">(5.1, 7.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">(4.4, 7.9)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">% 1-year Survival
</td>
<td class="Rrule" align="center" valign="top">37%**<span class="Sup">†</span>
</td>
<td class="Rrule" align="center" valign="top">12%
</td>
<td class="Rrule" align="center" valign="top">30%**<span class="Sup">†</span>
</td>
<td class="Rrule" align="center" valign="top">20%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Botrule Rrule" align="center" valign="top">(24, 50)
</td>
<td class="Botrule Rrule" align="center" valign="top">(2, 23)
</td>
<td class="Botrule Rrule" align="center" valign="top">(22, 39)
</td>
<td class="Botrule Rrule" align="center" valign="top">(13, 27)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Time to Progression
</td>
<td class="Rrule" align="center" valign="top">12.3 weeks**
</td>
<td class="Rrule" align="center" valign="top">7.0 weeks
</td>
<td class="Rrule" align="center" valign="top">8.3 weeks
</td>
<td class="Rrule" align="center" valign="top">7.6 weeks
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Botrule Rrule" align="center" valign="top">(9.0, 18.3)
</td>
<td class="Botrule Rrule" align="center" valign="top">(6.0, 9.3)
</td>
<td class="Botrule Rrule" align="center" valign="top">(7.0, 11.7)
</td>
<td class="Botrule Rrule" align="center" valign="top">(6.7, 10.1)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Response Rate
</td>
<td class="Rrule" align="center" valign="top">5.5%
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">5.7%
</td>
<td class="Rrule" align="center" valign="top">0.8%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">Not
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Botrule Rrule" align="center" valign="top">(1.1, 15.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">Applicable
</td>
<td class="Botrule Rrule" align="center" valign="top">(2.3, 11.3)
</td>
<td class="Botrule Rrule" align="center" valign="top">(0.0, 4.5)
</td>
</tr>
</tbody>
</table>
<p>Only one of the two trials (TAX317) showed a clear effect on survival, the primary endpoint; that trial also showed an increased rate of survival to one year. In the second study (TAX320) the rate of survival at one year favored docetaxel injection concentrate 75 mg/m<span class="Sup">2</span>.<br><br></p>
<p class="MultiMediaCaption"><a name="fig3"></a><span class="Bold">Figure 3 - TAX317 Survival K-M Curves - Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">vs. Best Supportive Care</span><br><br></p>
<div class="Figure">
<a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-04.jpg">
</div>
<p class="MultiMediaCaption"><a name="fig4"></a><span class="Bold">Figure 4 - TAX320 Survival K-M Curves - Docetaxel Injection Concentrate 75 mg/m</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">vs. Vinorelbine or Ifosfamide Control</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-05.jpg">
</div>
<p>Patients treated with docetaxel injection concentrate at a dose of 75 mg/m<span class="Sup">2</span> experienced no deterioration in performance status and body weight relative to the comparator arms used in these trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-13.3.2"></a><p></p>
<p class="First"><span class="Underline">Combination Therapy with Docetaxel Injection Concentrate for Chemotherapy-Naïve NSCLC</span></p>
<p>In a randomized controlled trial (TAX326), 1218 patients with unresectable stage IIIB or IV NSCLC and no prior chemotherapy were randomized to receive one of three treatments: Docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> as a 1 hour infusion immediately followed by cisplatin 75 mg/m<span class="Sup">2</span> over 30 to 60 minutes every 3 weeks; vinorelbine 25 mg/m<span class="Sup">2</span> administered over 6 to 10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m<span class="Sup">2</span> administered on day 1 of cycles repeated every 4 weeks; or a combination of docetaxel injection concentrate and carboplatin.
</p>
<p>The primary efficacy endpoint was overall survival. Treatment with docetaxel injection concentrate+cisplatin did not result in a statistically significantly superior survival compared to vinorelbine+cisplatin (see table below). The 95% confidence interval of the hazard ratio (adjusted for interim analysis and multiple comparisons) shows that the addition of docetaxel injection concentrate to cisplatin results in an outcome ranging from a 6% inferior to a 26% superior survival compared to the addition of vinorelbine to cisplatin. The results of a further statistical analysis showed that at least (the lower bound of the 95% confidence interval) 62% of the known survival effect of vinorelbine when added to cisplatin (about a 2-month increase in median survival; Wozniak et al. JCO, 1998) was maintained. The efficacy data for the docetaxel injection concentrate+cisplatin arm and the comparator arm are summarized in <a href="#t16">Table 16</a>.
</p>
<a name="t16"></a><table width="100%">
<caption><span>Table 16 - Survival Analysis of Docetaxel Injection Concentrate in Combination Therapy for Chemotherapy-Naïve NSCLC
</span></caption>
<col align="left" width="50.067%">
<col align="left" width="24.933%">
<col align="left" width="25.000%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> From the superiority test (stratified log rank) comparing docetaxel injection concentrate+cisplatin to vinorelbine+cisplatin
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span>Hazard ratio of docetaxel injection concentrate+cisplatin vs. vinorelbine+cisplatin. A hazard ratio of less than 1 indicates that docetaxel injection concentrate+cisplatin is associated with a longer survival.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span>Adjusted for interim analysis and multiple comparisons.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Comparison
</td>
<td class="Rrule Toprule" align="center" valign="top">Docetaxel Injection Concentrate+Cisplatin
</td>
<td class="Rrule Toprule" align="center" valign="top">Vinorelbine+Cisplatin
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">n=408
</td>
<td class="Botrule Rrule" align="center" valign="top">n=405
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Kaplan-Meier Estimate of Median Survival
</td>
<td class="Botrule Rrule" align="center" valign="top">10.9 months
</td>
<td class="Botrule Rrule" align="center" valign="top">10.0 months
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">p-value<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.122
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Estimated Hazard Ratio<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.88
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Adjusted 95% CI<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">(0.74, 1.06)
</td>
</tr>
</tbody>
</table>
<p>The second comparison in the same three-arm study, vinorelbine+cisplatin versus docetaxel injection concentrate+carboplatin, did not demonstrate superior survival associated with the docetaxel injection concentrate arm (Kaplan-Meier estimate of median survival was 9.1 months for docetaxel injection concentrate+carboplatin compared to 10.0 months on the vinorelbine+cisplatin arm) and the docetaxel injection concentrate+carboplatin arm did not demonstrate preservation of at least 50% of the survival effect of vinorelbine added to cisplatin. Secondary endpoints evaluated in the trial included objective response and time to progression. There was no statistically significant difference between docetaxel injection concentrate+cisplatin and vinorelbine+cisplatin with respect to objective response and time to progression (see <a href="#t17">Table 17</a>).
</p>
<a name="t17"></a><table width="100%">
<caption><span>Table 17 - Response and TTP Analysis of Docetaxel Injection Concentrate in Combination Therapy for Chemotherapy-Naïve NSCLC
</span></caption>
<col align="left" width="30.967%">
<col align="left" width="25.894%">
<col align="left" width="25.019%">
<col align="left" width="18.120%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">a</span>Adjusted for multiple comparisons.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">b</span>Kaplan-Meier estimates.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Endpoint
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Docetaxel Injection Concentrate+Cisplatin
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Vinorelbine+Cisplatin
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">p-value
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Objective Response Rate
</td>
<td class="Botrule Rrule" align="center" valign="top">31.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">24.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">Not Significant
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">(95% CI)<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">(26.5%, 36.8%)
</td>
<td class="Botrule Rrule" align="center" valign="top">(19.8%, 29.2%)
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median Time to
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Progression<span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="bottom">21.4 weeks
</td>
<td class="Rrule" align="center" valign="bottom">22.1 weeks
</td>
<td class="Rrule" align="center" valign="middle">Not Significant
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">(95% CI)<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(19.3, 24.6)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(18.1, 25.6)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Hormone Refractory Prostate Cancer
</h2>
<p class="First">The safety and efficacy of docetaxel injection concentrate in combination with prednisone in patients with androgen independent (hormone refractory) metastatic prostate cancer were evaluated in a randomized multicenter active control trial. A total of 1006 patients with Karnofsky Performance Status (KPS) ≥60 were randomized to the following treatment groups:
</p>
<ul class="Disc">
<li>Docetaxel injection concentrate 75 mg/m<span class="Sup">2</span> every 3 weeks for 10 cycles.
</li>
<li>Docetaxel injection concentrate 30 mg/m<span class="Sup">2</span> administered weekly for the first 5 weeks in a 6-week cycle for 5 cycles.
</li>
<li>Mitoxantrone 12 mg/m<span class="Sup">2</span> every 3 weeks for 10 cycles.
</li>
</ul>
<p>All 3 regimens were administered in combination with prednisone 5 mg twice daily, continuously.
</p>
<p>In the docetaxel injection concentrate every three week arm, a statistically significant overall survival advantage was demonstrated compared to mitoxantrone. In the docetaxel injection concentrate weekly arm, no overall survival advantage was demonstrated compared to the mitoxantrone control arm. Efficacy results for the docetaxel injection concentrate every 3 week arm versus the control arm are summarized in <a href="#t18">Table 18</a> and <a href="#fig5">Figure 5</a>.
</p>
<a name="t18"></a><table width="100%">
<caption><span>Table 18 - Efficacy of Docetaxel Injection Concentrate in the Treatment of Patients with Androgen Independent (Hormone Refractory) Metastatic Prostate Cancer (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="33.800%">
<col align="left" width="32.533%">
<col align="left" width="33.667%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Stratified log rank test. Threshold for statistical significance = 0.0175 because of 3 arms.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Rrule Toprule" align="center" valign="middle"><span class="Bold">Docetaxel Injection Concentrate+ Prednisone</span></td>
<td class="Rrule Toprule" align="center" valign="middle"><span class="Bold">Mitoxantrone+ Prednisone</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">every 3 weeks</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">every 3 weeks</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Number of patients
</td>
<td class="Rrule" align="center" valign="top">335
</td>
<td class="Rrule" align="center" valign="top">337
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median survival (months)
</td>
<td class="Rrule" align="center" valign="top">18.9
</td>
<td class="Rrule" align="center" valign="top">16.5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Rrule" align="center" valign="top">(17.0 to 21.2)
</td>
<td class="Rrule" align="center" valign="top">(14.4 to 18.6)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hazard ratio
</td>
<td class="Rrule" align="center" valign="top">0.761
</td>
<td class="Rrule" align="center" valign="top">--
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">95% CI
</td>
<td class="Rrule" align="center" valign="top">(0.619 to 0.936)
</td>
<td class="Rrule" align="center" valign="top">--
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">p-value*
</td>
<td class="Botrule Rrule" align="center" valign="top">0.0094
</td>
<td class="Botrule Rrule" align="center" valign="top">--
</td>
</tr>
</tbody>
</table>
<p class="MultiMediaCaption"><a name="fig5"></a><span class="Bold">Figure 5 -TAX327 Survival K-M Curves</span></p>
<div class="Figure">
<a name="f06"></a><img alt="Figure 5
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Gastric Adenocarcinoma
</h2>
<p class="First">A multicenter, open-label, randomized trial was conducted to evaluate the safety and efficacy of docetaxel injection concentrate for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for advanced disease. A total of 445 patients with KPS &gt;70 were treated with either docetaxel injection concentrate (T) (75 mg/m<span class="Sup">2</span> on day 1) in combination with cisplatin (C) (75 mg/m<span class="Sup">2</span> on day 1) and fluorouracil (F) (750 mg/m<span class="Sup">2</span> per day for 5 days) or cisplatin (100 mg/m<span class="Sup">2</span> on day 1) and fluorouracil (1000 mg/m<span class="Sup">2</span> per day for 5 days). The length of a treatment cycle was 3 weeks for the TCF arm and 4 weeks for the CF arm. The demographic characteristics were balanced between the two treatment arms. The median age was 55 years, 71% were male, 71% were Caucasian, 24% were 65 years of age or older, 19% had a prior curative surgery and 12% had palliative surgery. The median number of cycles administered per patient was 6 (with a range of 1 to 16) for the TCF arm compared to 4 (with a range of 1 to 12) for the CF arm. Time to progression (TTP) was the primary endpoint and was defined as time from randomization to disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause within 12 weeks of the last evaluable tumor assessment or within 12 weeks of the first infusion of study drugs for patients with no evaluable tumor assessment after randomization. The hazard ratio (HR) for TTP was 1.47 (CF/TCF, 95% CI: 1.19 to 1.83) with a significantly longer TTP (p=0.0004) in the TCF arm. Approximately 75% of patients had died at the time of this analysis. Overall survival was significantly longer (p=0.0201) in the TCF arm with a HR of 1.29 (95% CI: 1.04 to 1.61). Efficacy results are summarized in <a href="#t19">Table 19</a> and <a href="#fig3">Figures 6</a> and <a href="#fig3">7</a>.
</p>
<a name="t19"></a><table width="100%">
<caption><span>Table 19 - Efficacy of Docetaxel Injection Concentrate in the treatment of patients with Gastric Adenocarcinoma
</span></caption>
<col align="left" width="55.100%">
<col align="left" width="22.433%">
<col align="left" width="22.467%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Unstratified log-rank test
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">†</span>For the hazard ratio (TCF/CF), values less than 1.00 favor the docetaxel injection concentrate arm.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Endpoint</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">TCF</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">CF</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=221</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=224</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median TTP (months)
</td>
<td class="Rrule" align="center" valign="top">5.6
</td>
<td class="Rrule" align="center" valign="top">3.7
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="top">(4.86 to 5.91)
</td>
<td class="Botrule Rrule" align="center" valign="top">(3.45 to 4.47)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hazard ratio<span class="Sup">†</span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.68
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.55 to 0.84)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">*p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0004
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median survival (months)
</td>
<td class="Rrule" align="center" valign="top">9.2
</td>
<td class="Rrule" align="center" valign="top">8.6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="top">(8.38 to 10.58)
</td>
<td class="Botrule Rrule" align="center" valign="top">(7.16 to 9.46)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hazard ratio<span class="Sup">†</span>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.77
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.62 to 0.96)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">*p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0201
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Overall Response Rate (CR+PR) (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">36.7
</td>
<td class="Botrule Rrule" align="center" valign="top">25.4
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0106
</td>
</tr>
</tbody>
</table>
<p>Subgroup analyses were consistent with the overall results across age, gender and race.<br><br></p>
<p class="MultiMediaCaption"><a name="fig6"></a><span class="Bold">Figure 6 -Gastric Cancer Study (TAX325) Time to Progression K-M Curve</span></p>
<div class="Figure">
<a name="f07"></a><img alt="Figure 6
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-07.jpg">
</div>
<p class="MultiMediaCaption"><a name="fig7"></a><span class="Bold">Figure 7 -Gastric Cancer Study (TAX325) Survival K-M Curve</span></p>
<div class="Figure">
<a name="f08"></a><img alt="Figure 7
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s118"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Head and Neck Cancer
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-13.6.1"></a><p></p>
<p class="First"><span class="Underline">Induction chemotherapy followed by radiotherapy (TAX323)</span></p>
<p>The safety and efficacy of docetaxel injection concentrate in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a multicenter, open-label, randomized trial (TAX323). In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms. Patients on the docetaxel injection concentrate arm received docetaxel injection concentrate (T) 75 mg/m<span class="Sup">2</span> followed by cisplatin (P) 75 mg/m<span class="Sup">2</span> on Day 1, followed by fluorouracil (F) 750 mg/m<span class="Sup">2</span> per day as a continuous infusion on Days 1 to 5. The cycles were repeated every three weeks for 4 cycles. Patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines (TPF/RT). Patients on the comparator arm received cisplatin (P) 100 mg/m<span class="Sup">2</span> on Day 1, followed by fluorouracil (F) 1000 mg/m<span class="Sup">2</span>/day as a continuous infusion on Days 1 to 5. The cycles were repeated every three weeks for 4 cycles. Patients whose disease did not progress received RT according to institutional guidelines (PF/RT). At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines. Locoregional therapy with radiation was delivered either with a conventional fraction regimen (1.8 Gy to 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy) or with an accelerated/hyperfractionated regimen (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week, for a total dose of 70 to 74 Gy, respectively). Surgical resection was allowed following chemotherapy, before or after radiotherapy.
</p>
<p>The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p=0.0077 (median PFS: 11.4 vs. 8.3 months respectively) with an overall median follow up time of 33.7 months. Median overall survival with a median follow-up of 51.2 months was also significantly longer in favor of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.2 months respectively). Efficacy results are presented in <a href="#t20">Table 20</a> and <a href="#fig8">Figures 8</a> and <a href="#fig9">9</a>.
</p>
<a name="t20"></a><table width="100%">
<caption><span>Table 20 - Efficacy of Docetaxel Injection Concentrate in the Induction Treatment of Patients with Inoperable Locally Advanced SCCHN (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="56.233%">
<col align="left" width="21.333%">
<col align="left" width="22.433%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">A Hazard ratio of less than 1 favors docetaxel injection concentrate+Cisplatin+Fluorouracil
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">* Stratified log-rank test based on primary tumor site
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">** Stratified log-rank test, not adjusted for multiple comparisons
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*** Chi square test, not adjusted for multiple comparisons
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Endpoint</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Docetaxel Injection Concentrate+</span></td>
<td class="Rrule Toprule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Cisplatin+</span></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Cisplatin+</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Fluorouracil</span></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Fluorouracil</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=177</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">n=181</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median progression free survival (months)
</td>
<td class="Rrule" align="center" valign="top">11.4
</td>
<td class="Rrule" align="center" valign="top">8.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="top">(10.1 to 14.0)
</td>
<td class="Botrule Rrule" align="center" valign="top">(7.4 to 9.1)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Adjusted Hazard ratio
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.71
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.56 to 0.91)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">*p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0077
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median survival (months)
</td>
<td class="Rrule" align="center" valign="top">18.6
</td>
<td class="Rrule" align="center" valign="top">14.2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="top">(15.7 to 24.0)
</td>
<td class="Botrule Rrule" align="center" valign="top">(11.5 to 18.7)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hazard ratio
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.71
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.56 to 0.90)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">**p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0055
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Best overall response (CR + PR) to
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">chemotherapy (%)
</td>
<td class="Rrule" align="center" valign="bottom">67.8
</td>
<td class="Rrule" align="center" valign="bottom">53.6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(60.4 to 74.6)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(46.0 to 61.0)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">***p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">0.006
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Best overall response (CR + PR) to study
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">treatment [chemotherapy +/- radiotherapy] (%)
</td>
<td class="Rrule" align="center" valign="bottom">72.3
</td>
<td class="Rrule" align="center" valign="bottom">58.6
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95%CI)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(65.1 to 78.8)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(51.0 to 65.8)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">***p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">0.006
</td>
</tr>
</tbody>
</table>
<p class="MultiMediaCaption"><a name="fig8"></a><span class="Bold">Figure 8 -TAX323 Progression-Free Survival K-M Curve</span></p>
<div class="Figure">
<a name="f09"></a><img alt="Figure 8
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-09.jpg">
</div>
<p class="MultiMediaCaption"><a name="fig9"></a><span class="Bold">Figure 9 -TAX323 Overall Survival K-M Curve</span></p>
<div class="Figure">
<a name="f10"></a><img alt="Figure 9
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s120"></a><a name="section-13.6.2"></a><p></p>
<p class="First"><span class="Underline">Induction chemotherapy followed by chemoradiotherapy (TAX324)</span></p>
<p>The safety and efficacy of docetaxel injection concentrate in the induction treatment of patients with locally advanced (unresectable, low surgical cure, or organ preservation) SCCHN was evaluated in a randomized, multicenter open-label trial (TAX324). In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two treatment arms. Patients on the docetaxel injection concentrate arm received docetaxel injection concentrate (T) 75 mg/m<span class="Sup">2</span> by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m<span class="Sup">2</span> administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of fluorouracil (F) 1000 mg/m<span class="Sup">2</span>/day from day 1 to day 4. The cycles were repeated every 3 weeks for 3 cycles. Patients on the comparator arm received cisplatin (P) 100 mg/m<span class="Sup">2</span> as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of fluorouracil (F) 1000 mg/m<span class="Sup">2</span>/day from day 1 to day 5. The cycles were repeated every 3 weeks for 3 cycles.
</p>
<p>All patients in both treatment arms who did not have progressive disease were to receive 7 weeks of chemoradiotherapy (CRT) following induction chemotherapy 3 to 8 weeks after the start of the last cycle. During radiotherapy, carboplatin (AUC 1.5) was given weekly as a one-hour intravenous infusion for a maximum of 7 doses. Radiation was delivered with megavoltage equipment using once daily fractionation (2 Gy per day, 5 days per week for 7 weeks for a total dose of 70 to 72 Gy). Surgery on the primary site of disease and/or neck could be considered at anytime following completion of CRT.
</p>
<p>The primary efficacy endpoint, overall survival (OS), was significantly longer (log-rank test, p=0.0058) with the docetaxel injection concentrate-containing regimen compared to PF [median OS: 70.6 versus 30.1 months respectively, hazard ratio (HR)=0.70, 95% confidence interval (CI)= 0.54 – 0.90]. Overall survival results are presented in <a href="#t21">Table 21</a> and <a href="#fig10">Figure 10</a>.
</p>
<a name="t21"></a><table width="100%">
<caption><span>Table 21 - Efficacy of Docetaxel Injection Concentrate in the Induction Treatment of Patients with Locally Advanced SCCHN (Intent-to-Treat Analysis)
</span></caption>
<col align="left" width="44.033%">
<col align="left" width="33.067%">
<col align="left" width="22.900%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">A Hazard ratio of less than 1 favors docetaxel injection concentrate+cisplatin+fluorouracil
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">* un-adjusted log-rank test
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">NE - not estimable
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Docetaxel Injection Concentrate+</span></td>
<td class="Rrule Toprule" align="center" valign="top"><span class="Bold">Cisplatin+</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="bottom"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Cisplatin+Fluorouracil</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Fluorouracil</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Endpoint</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=255</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n=246</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median overall survival (months)
</td>
<td class="Rrule" align="center" valign="top">70.6
</td>
<td class="Rrule" align="center" valign="top">30.1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">(95% CI)
</td>
<td class="Botrule Rrule" align="center" valign="top">(49.0 to NE)
</td>
<td class="Botrule Rrule" align="center" valign="top">(20.9 to 51.5)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hazard ratio:
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.70
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">(95% CI)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.54 to 0.90)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">*p-value
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.0058
</td>
</tr>
</tbody>
</table>
<p class="MultiMediaCaption"><a name="fig10"></a><span class="Bold">Figure 10 - TAX324 Overall Survival K-M Curve</span></p>
<div class="Figure">
<a name="f11"></a><img alt="Figure 10
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0000-11.jpg">
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s121"></a><a name="section-14"></a><p></p>
<h1>15. REFERENCES
</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</span>
</li>
<li>American Society of Health-System Pharmacists. (2006) ASHP Guidelines on Handling Hazardous Drugs. Am J Health-Syst Pharm. 2006;63:1172-1193
</li>
<li>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s122"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s123"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s124"></a><a name="section-15.1.1"></a><p></p>
<p class="First"><span class="Bold Underline">One-vial Docetaxel Injection Concentrate</span></p>
<p>Docetaxel Injection Concentrate is supplied as follows:
</p>
<table width="100%">
<col align="left" width="21.160%">
<col align="left" width="41.953%">
<col align="left" width="36.888%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold">Docetaxel Injection Concentrate</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top">
<span class="Bold">(20 mg per mL</span>)
</td>
<td align="left" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="left" valign="top">25021-222-01
</td>
<td align="left" valign="top">20 mg per mL Single-Use Vial
</td>
<td align="left" valign="top">1 vial per carton
</td>
</tr>
<tr>
<td align="left" valign="top">25021-222-04
</td>
<td align="left" valign="top">80 mg per 4 mL Single-Use Vial
</td>
<td align="left" valign="top">1 vial per carton
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">25021-222-07
</td>
<td align="left" valign="top">140 mg per 7 mL Single-Use Vial
</td>
<td align="left" valign="top">1 vial per carton
</td>
</tr>
</tbody>
</table>
<p>Docetaxel Injection Concentrate is supplied in glass vials as a non-aqueous, clear, viscous, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution, without macroscopic particles in solution at 20 mg/mL concentration.
</p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s125"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage
</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Retain in the original package to protect from light.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s126"></a><a name="section-15.3"></a><p></p>
<h2>16.3 Handling and Disposal
</h2>
<p class="First">Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published <span class="Italics">[see References (<a href="#s121">15</a>)]</span>.
</p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s127"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION
</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling (<a href="#s128">Patient Information</a>)</span></p>
<ul class="Disc">
<li>Docetaxel injection concentrate may cause fetal harm. Advise patients to avoid becoming pregnant while receiving this drug. Women of childbearing potential should use effective contraceptives if receiving docetaxel injection concentrate [<span class="Italics">see Warnings and Precautions (<a href="#s49">5.10</a>) and Use in Specific Populations (<a href="#s80">8.1</a>)]</span>.
</li>
<li>Obtain detailed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> and concomitant drug information from the patient prior to docetaxel injection concentrate administration.
</li>
<li>Explain the significance of oral corticosteroids such as dexamethasone administration to the patient to help facilitate compliance. Instruct patients to report if they were not compliant with oral corticosteroid regimen.
</li>
<li>Instruct patients to immediately report signs of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.
</li>
<li>Tell patients to watch for signs of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> such as <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> in the lower extremities, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.
</li>
<li>Explain the significance of routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.
</li>
<li>Instruct patients to report <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, cutaneous, or <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic reactions</span>.
</li>
<li>Explain to patients that side effects such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, excessive tearing, infusion site reactions, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> are associated with docetaxel administration.
</li>
</ul>
<p>SAGENT™
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA) <br>Made in Romania<br>©2013 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: November 2013
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s128"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p>Docetaxel (doe-se-TAKS-el) Injection Concentrate
</p>
<p>Intravenous Infusion
</p>
<p>Read this Patient Information before you receive your first treatment with docetaxel injection concentrate and each time before you are treated. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
</p>
<p><a name="p01"></a><span class="Bold">What is the most important information I should know about docetaxel injection concentrate?</span></p>
<p><span class="Bold">Docetaxel injection concentrate can cause serious side effects, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<ol class="Arabic">
<li>
<span class="Bold"> The chance of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in people who receive docetaxel injection concentrate is higher if you:</span><ul class="Disc">
<li>have liver problems
</li>
<li>receive high doses of docetaxel injection concentrate
</li>
<li>have non-small cell lung cancer and have been treated with chemotherapy medicines that contain platinum
</li>
</ul>
</li>
<li>
<span class="Bold"> Docetaxel injection concentrate can affect your blood cells.</span> Your doctor should do routine blood tests during treatment with docetaxel injection concentrate. This will include regular checks of your white blood cell counts. If your white blood cells are too low, your doctor may not treat you with docetaxel injection concentrate until you have enough white blood cells. People with low white blood counts can develop life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The earliest sign of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Follow your doctor's instructions for how often to take your temperature while taking docetaxel injection concentrate. Call your doctor right away if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.
</li>
<li>
<span class="Bold"> Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span> can happen in people who take docetaxel injection concentrate. Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> are medical emergencies that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated right away.<br>Tell your doctor right away if you have any of these signs of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:<ul class="Disc">
<li>trouble breathing
</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, tongue, throat, or trouble swallowing
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> (raised bumps), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> all over your body
</li>
</ul>
</li>
<li>
<span class="Bold"> Your body may hold too much fluid (severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</span> during treatment with docetaxel injection concentrate. This can be life threatening. To decrease the chance of this happening, you must take another medicine, a corticosteroid, before each docetaxel injection concentrate treatment. You must take the corticosteroid exactly as your doctor tells you. Tell your doctor or nurse before your docetaxel injection concentrate treatment if you forget to take corticosteroid dose or do not take it as your doctor tells you.
</li>
</ol>
<p><span class="Bold">What is docetaxel injection concentrate?</span></p>
<p>Docetaxel injection concentrate is a prescription anti-cancer medicine used to treat certain people with:
</p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li>breast cancer
</li>
<li>non-small cell lung cancer
</li>
<li>prostate cancer<br>
</li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li>stomach cancer
</li>
<li>head and neck cancer<br>
</li>
</ul></td>
</tr></tbody>
</table>
<p>The effectiveness of docetaxel injection concentrate in children has not been established.
</p>
<p><a name="p02"></a><span class="Bold">Who should not take docetaxel injection concentrate?</span></p>
<p><span class="Bold">Do not take docetaxel injection concentrate if you:</span></p>
<ul class="Disc">
<li>have had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to:<ul class="Circle">
<li>docetaxel, the active ingredient in docetaxel injection concentrate, or
</li>
<li>any other medicines that contain polysorbate 80. Ask your doctor or pharmacist if you are not sure.
</li>
<li>See “<a href="#p01">What is the most important information I should know about docetaxel injection concentrate?</a>? for the signs and symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.
</li>
</ul>
</li>
<li>have a low white blood cell count.
</li>
</ul>
<p><span class="Bold">What should I tell my doctor before receiving docetaxel injection concentrate?</span></p>
<p>Before you receive docetaxel injection concentrate, tell your doctor if you:
</p>
<ul class="Disc">
<li>are allergic to any medicines. See “<a href="#p02">Who should not take docetaxel injection concentrate?</a>? Also, see the end of this leaflet for a complete list of the ingredients in docetaxel injection concentrate.
</li>
<li>have liver problems.
</li>
<li>have any other medical conditions.
</li>
<li>are pregnant or plan to become pregnant. Docetaxel injection concentrate can harm your unborn baby.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if docetaxel injection concentrate passes into your breast milk. You and your doctor should decide if you will take docetaxel injection concentrate or breastfeed.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Docetaxel injection concentrate may affect the way other medicines work, and other medicines may affect the way docetaxel injection concentrate works.
</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How will I receive docetaxel injection concentrate?</span></p>
<ul class="Disc">
<li>Docetaxel injection concentrate will be given to you as an intravenous (IV) injection into your vein, usually over 1 hour.
</li>
<li>Docetaxel injection concentrate is usually given every 3 weeks.
</li>
<li>Your doctor will decide how long you will receive treatment with docetaxel injection concentrate.
</li>
<li>Your doctor will check your blood cell counts and other blood tests during your treatment with docetaxel injection concentrate to check for side effects of docetaxel injection concentrate.
</li>
<li>Your doctor may stop your treatment, change the timing of your treatment, or change the dose of your treatment if you have certain side effects while taking docetaxel injection concentrate.
</li>
</ul>
<p><span class="Bold">What are the possible side effects of docetaxel injection concentrate?</span></p>
<p><span class="Bold">Docetaxel injection concentrate may cause serious side effects including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<ul class="Disc">
<li>See “<a href="#p01">What is the most important information I should know about docetaxel injection concentrate?</a>?
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute Myeloid Leukemia</span> (AML)</span>, a type of blood cancer, can happen in people who take docetaxel injection concentrate along with certain other medicines.
</li>
<li>
<span class="Bold">Other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Disorders</span>.</span>  Changes in blood counts due to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> may occur years after treatment with docetaxel injection concentrate.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span> including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your arms and legs with <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span></span> including <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or burning in your hands and feet.
</li>
</ul>
<p>The most common side effects of docetaxel injection concentrate include:
</p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li>changes in your sense of taste
</li>
<li>feeling <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>
</li>
<li>changes in your fingernails or toenails
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands, face or feet
</li>
<li>feeling weak or tired
</li>
<li>joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li>mouth or lips sores
</li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the eye, excess tearing
</li>
<li><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the site of docetaxel injection concentrate administration such as increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, warmth or dryness of the skin
</li>
<li>tissue damage if docetaxel injection concentrate leaks out of the vein into the tissues
</li>
</ul></td>
</tr></tbody>
</table>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.
</p>
<p>These are not all the possible side effects of docetaxel injection concentrate.  For more information ask your doctor or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">General information about docetaxel injection concentrate</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. This Patient Information leaflet summarizes the most important information about docetaxel injection concentrate. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about docetaxel injection concentrate that is written for health professionals.
</p>
<p>For more information call Sagent Pharmaceuticals, Inc. at 1-866-625-1618.
</p>
<p><span class="Bold">What are the ingredients in docetaxel injection concentrate?</span></p>
<p><span class="Bold">Active ingredient</span>: docetaxel
</p>
<p><span class="Bold">Inactive ingredients</span> : citric acid anhydrous, kollidon 12 PF (povidone P12), polysorbate 80 and ethanol
</p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Every three-week injection of docetaxel injection concentrate for breast, non-small cell lung and stomach, and head and neck cancers</span><br><span class="Bold">Take your oral corticosteroid medicine as your doctor tells you.</span><br><br><span class="Bold">Oral corticosteroid
</span><span class="Bold Italics">dosing:</span><br><br>Day 1 Date: ________ Time:_____ AM ______ PM<br>Day 2 Date: ________ Time:_____ AM ______ PM<br><span class="Bold">(Docetaxel Injection Concentrate Treatment Day)</span><br><br>Day 3 Date: ________ Time:_____ AM ______ PM
</td></tr></tbody>
</table>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Every three-week injection of docetaxel injection concentrate for prostate cancer</span><br><span class="Bold">Take your oral corticosteroid medicine as your doctor tells you.</span><br><br><span class="Bold Italics">Oral corticosteroid dosing:</span><br><br>Date: _________    Time: ________<br><br>Date: _________    Time: ________<br><span class="Bold">(Docetaxel Injection Concentrate Treatment Day)</span><br>Time: ________<br>
</td></tr></tbody>
</table>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.
</p>
<p>SAGENT™
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA) <br>Made in Romania<br>©2013 Sagent Pharmaceuticals, Inc.
</p>
<p>June 2013
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s129"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label</span></p>
<p>NDC 25021-222-01
</p>
<p>1 mL Single-Use Vial
</p>
<p><span class="Bold">Docetaxel</span> Injection Concentrate
</p>
<p><span class="Bold">20</span> mg per mL
</p>
<p>For Intravenous Infusion Only
</p>
<p>Rx only
</p>
<p>Ready to add to infusion solutions
</p>
<p>Caution: Cytotoxic Agent
</p>
<div class="Figure">
<a name="f12"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70aeb960-426c-4805-b956-476bebccd926&amp;name=doc03-0001-12.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOCETAXEL 		
					</strong><br><span class="contentTableReg">docetaxel solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-222</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>docetaxel</strong> (docetaxel anhydrous) </td>
<td class="formItem">docetaxel anhydrous</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone k12</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-222-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:25021-222-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:25021-222-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">7 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203551</td>
<td class="formItem">07/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3fead05a-55de-421f-bed1-bc208c99beae</div>
<div>Set id: 70aeb960-426c-4805-b956-476bebccd926</div>
<div>Version: 3</div>
<div>Effective Time: 20131106</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
